Reagent and method for detecting AAV shedding
By contacting the sample with a specific primer and probe composition and carrying out polymerase chain reaction, the accurate quantification problem of viral vector shedding titer measurement in gene therapy is solved, and accurate quantification detection of AAV constructs is achieved to ensure that The accuracy and repeatability of safety monitoring are achieved.
Patent Information
- Application Number
- CN202411030195.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-29
- Filing Date
- 2020-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to provide accurate quantification and repeatable mechanisms to measure shedding titers of viral particles in patients, especially in the monitoring of safety of viral vectors in gene therapy.
Compositions containing specific primers and probes are provided for contacting samples from subjects, generating amplicons by polymerase chain reaction, and detecting the level of hybridization between the probe and the amplicon for quantitative analysis AAV construct or fragment thereof in the sample.
Accurate quantitative detection of AAV constructs or fragments thereof is achieved, ensuring the accuracy and repeatability of safety monitoring of viral vectors in gene therapy.
Smart Images

Figure CN119061198A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with the application date of August 29, 2020, application number 202080060875.4, and invention name “Reagents and methods for detecting AAV shedding”.
[0002] This application incorporates by reference the Sequence Listing submitted with this application in computer readable form, which has the file name of 2918P21346WO_SeqListing.txt and is 14.4 KB in size. Technical Field
[0003] The present application relates to AAV detection, and in particular provides primers and probes for detecting shedding of AAV constructs or fragments thereof in a subject. Background Art
[0004] The field of gene therapy is advancing at an astonishing pace. To facilitate this progress, appropriate safety standards must be met. When utilizing viral vectors for delivering gene therapy, a key safety variable to measure is the viral particles released and / or shed from the patient. There remains a pressing need for an accurate and reproducible mechanism for measuring viral shedding titers in patients. Summary of the invention
[0005] The present disclosure provides compositions and methods useful for accurately quantifying certain viral particles (eg, in a sample from a subject, such as a human).
[0006] In some embodiments, the present disclosure provides compositions comprising a collection of primers. In some embodiments, the compositions comprise a collection of primers and one or more probes.
[0007] In some embodiments, the set of primers comprises one or more forward primers. In some embodiments, at least one forward primer has a nucleotide sequence according to SEQ ID NO: 1 or an active fragment thereof.
[0008] In some embodiments, the set of primers comprises one or more reverse primers. In some embodiments, at least one reverse primer has a nucleotide sequence according to SEQ ID NO: 11 or an active fragment thereof.
[0009] In some embodiments, at least one probe has a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof.
[0010] In some embodiments, the composition comprises a collection of primers and one or more probe sequences, wherein at least one primer has a nucleotide sequence according to SEQ ID NO:1 or an active fragment thereof, at least one primer has a nucleotide sequence according to SEQ ID NO:11 or an active fragment thereof, and at least one probe has a nucleotide sequence according to SEQ ID NO:17 or an active fragment thereof.
[0011] In some embodiments, the composition comprises a sample. In some embodiments, the sample is obtained from a subject to whom a viral vector has been administered. In some embodiments, the viral vector is an AAV construct.
[0012] In some embodiments, the composition comprises a sample obtained from a subject to which a Duchenne muscular dystrophy (DMD) AAV construct has been administered. In some embodiments, the DMD AAV construct administered to the subject comprises one or more regulatory elements and one or more target therapeutic genes. In certain embodiments, the sample obtained from a subject to which a DMD AAV construct has been administered comprises a nucleic acid containing the DMD AAV construct or a fragment thereof. In certain embodiments, the DMD AAV construct comprises one or more regulatory elements, wherein the one or more regulatory elements comprise an enhancer, a promoter, a poly A signal sequence, or a combination thereof. In some embodiments, the DMD AAV construct comprises a target therapeutic gene containing a micro-dystrophin.
[0013] In some embodiments, compositions as described herein further include multiple amplicons. In some embodiments, an amplicon (e.g., each amplicon) includes: (a) a first chain, which includes: (i) a nucleotide sequence corresponding to the forward primer, and (ii) a nucleotide sequence corresponding to a portion of a DMD AAV construct or its fragment; (b) a second chain, which includes: (i) a nucleotide sequence of the reverse primer, and (ii) nucleotides complementary to a portion of a DMD AAV construct or its fragment; or (c) a combination thereof. In some embodiments, a portion of a DMD AAV construct or its fragment includes a nucleotide sequence spanning a connection between two regulatory elements, a connection between a construct and a regulatory element, or a connection between a regulatory element and a target therapeutic gene.
[0014] In some embodiments, the composition comprising multiple amplicons as described herein also comprises at least one or more probe sequences or their active fragments capable of hybridizing with amplicons. In some embodiments, the composition comprising multiple amplicons as described herein also comprises at least one or more probe sequences. In some embodiments, at least one probe sequence has a nucleotide sequence or active fragment according to SEQ ID NO:17 and can hybridize with amplicons. In some embodiments, one or more probe sequences are easy to detect. In some embodiments, the level of probe or probe-amplicons hybridization is quantifiable (for example, the level of fluorescence is quantifiable, the level of fluorescence quenching is quantifiable, the level of total amplicon amount is quantifiable, or free and / or hybridization probe is quantifiable).
[0015] In some embodiments, the disclosure provides methods comprising contacting a sample obtained from a subject with a composition as described herein, wherein a DMD AAV construct has been administered to the subject, and wherein the DMD AAV construct comprises one or more regulatory elements and a therapeutic gene of interest.
[0016] In some embodiments, the method includes amplifying the target sequence to generate multiple amplicons. In some embodiments, the target sequence is a DMD AAV construct or a fragment thereof. In some embodiments, each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence complementary to a portion of a DMD AAV construct or a fragment thereof; or (iii) a combination thereof. In some embodiments, a portion of a DMD AAV construct or a fragment thereof comprises a nucleotide sequence spanning a connection between two regulatory elements, a connection between a construct and a regulatory element, or a connection between a regulatory element and a target therapeutic gene.
[0017] In some embodiments of the methods described herein, the composition comprises a plurality of probes, each probe having a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof. In some embodiments, the composition comprises a plurality of probes, and at least a subset of the plurality of probes comprises a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof.
[0018] In some embodiments, the methods described herein include detecting the level of hybridization between multiple probes and multiple amplifiers. In some embodiments, the presence of hybridization indicates the DMD AAV construct in the sample. In some embodiments, the methods described herein include quantitatively detecting the level of hybridization between multiple probes and multiple amplifiers. In some embodiments, the amount of the DMD AAV construct in the sample is indicated by the amount of hybridization level.
[0019] The present disclosure provides compositions comprising a set of primers. In some embodiments, the compositions comprise a set of primers and one or more probes. In some embodiments, the set of primers comprises one or more forward primers. In some embodiments, at least one forward primer has a nucleotide sequence according to SEQ ID NO:35 or an active fragment thereof.
[0020] In some embodiments, the set of primers comprises one or more reverse primers. In some embodiments, at least one reverse primer has a nucleotide sequence according to SEQ ID NO: 45 or an active fragment thereof.
[0021] In some embodiments, at least one probe has a nucleotide sequence according to SEQ ID NO: 55 or an active fragment thereof.
[0022] In some embodiments, the composition comprises a collection of primers and one or more probe sequences, wherein at least one primer has a nucleotide sequence according to SEQ ID NO:35 or an active fragment thereof, at least one primer has a nucleotide sequence according to SEQ ID NO:45 or an active fragment thereof, and at least one probe has a nucleotide sequence according to SEQ ID NO:65 or an active fragment thereof.
[0023] In some embodiments, the composition comprises a sample obtained from a subject to which a hemophilia B (Hem-B) AAV construct has been administered. In some embodiments, the Hem-B AAV construct administered to the subject comprises one or more regulatory elements and one or more therapeutic genes of interest. In certain embodiments, the sample obtained from a subject to which a Hem-B AAV construct has been administered comprises a nucleic acid containing the Hem-B AAV construct or a fragment thereof. In certain embodiments, the Hem-B AAV construct comprises one or more regulatory elements, wherein the one or more regulatory elements comprise an enhancer, a promoter, a poly A signal sequence, or a combination thereof. In some embodiments, the Hem-B AAV construct comprises a therapeutic gene of interest containing factor IX.
[0024] In some embodiments, the compositions described herein further include multiple amplicons. In some embodiments, an amplicon (e.g., each amplicon) includes: (a) a first chain comprising: (i) a nucleotide sequence corresponding to the forward primer, and (ii) a nucleotide sequence corresponding to a portion of a Hem-B AAV construct or a fragment thereof; (b) a second chain comprising: (i) a nucleotide sequence of the reverse primer, and (ii) nucleotides complementary to a portion of a Hem-B AAV construct or a fragment thereof; or (c) a combination thereof. In some embodiments, a portion of a Hem-B AAV construct or a fragment thereof includes a nucleotide sequence spanning a connection between two regulatory elements, a connection between a construct and a regulatory element, or a connection between a regulatory element and a target therapeutic gene.
[0025] In some embodiments, the composition comprising multiple amplicons as described herein also comprises at least one or more probe sequences or their active fragments capable of hybridizing with amplicons. In some embodiments, the composition comprising multiple amplicons as described herein also comprises at least one or more probe sequences. In some embodiments, at least one probe sequence has a nucleotide sequence or active fragment according to SEQ ID NO:55 and can hybridize with amplicons. In some embodiments, one or more probe sequences are easy to detect. In some embodiments, the level of probe or probe-amplicon hybridization is quantifiable (for example, the level of fluorescence is quantifiable, the level of fluorescence quenching is quantifiable, the level of total amplicon amount is quantifiable, or free and / or hybridization probe is quantifiable).
[0026] In some embodiments, the present disclosure provides methods comprising contacting a sample obtained from a subject with a composition as described herein, wherein a Hem-B AAV construct has been administered to the subject, and wherein the Hem-B AAV construct comprises one or more regulatory elements and a therapeutic gene of interest.
[0027] In some embodiments, the method includes amplifying a target sequence to generate a plurality of amplicons. In some embodiments, the target sequence is a Hem-B AAV construct or a fragment thereof. In some embodiments, each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence complementary to a portion of the Hem-B AAV construct or a fragment thereof; or (iii) a combination thereof. In some embodiments, a portion of the Hem-B AAV construct or a fragment thereof comprises a nucleotide sequence spanning a junction between two regulatory elements, a junction between a construct and a regulatory element, or a junction between a regulatory element and a target therapeutic gene.
[0028] In some embodiments of the methods described herein, the composition comprises a plurality of probes, each probe having a nucleotide sequence according to SEQ ID NO: 55 or an active fragment thereof. In some embodiments, the composition comprises a plurality of probes, and at least a subset of the plurality of probes comprises a nucleotide sequence according to SEQ ID NO: 55 or an active fragment thereof.
[0029] In some embodiments, the methods described herein include detecting the level of hybridization between a plurality of probes and a plurality of amplicons. In some embodiments, the presence of hybridization indicates a Hem-B AAV construct in the sample. In some embodiments, the methods described herein include quantifying the level of hybridization between a plurality of probes and a plurality of amplicons. In some embodiments, the amount associated with the level of hybridization indicates the amount of the Hem-B AAV construct in the sample.
[0030] In some embodiments, the present disclosure provides a composition comprising a set of primers and / or a set of primers and probes, wherein one or more forward primers, one or more reverse primers, one or more probes, or a combination thereof are deoxyribonucleic acids. In some embodiments, the present disclosure provides a composition comprising a set of primers and / or a set of primers and probes, wherein one or more forward primers, one or more reverse primers, one or more probes, or a combination thereof are unmodified, modified, synthetic DNA, comprising an amino modifier, comprising a binding modifier, comprising a spacer, comprising an analog, comprising an insert, comprising an antisense portion, or any combination thereof. In some embodiments, the present disclosure provides a composition comprising a set of primers and / or a set of primers and probes, wherein one or more forward primers, one or more reverse primers, one or more probes, or a combination thereof are RNA. In some embodiments, the present disclosure provides a composition comprising a collection of primers and / or a collection of primers and probes, wherein one or more forward primers, one or more reverse primers, one or more probes, or a combination thereof are unmodified, modified, synthetic RNA, comprising an amino modifier, comprising a binding modifier, comprising a spacer, comprising an analog, comprising an inserter, comprising an antisense portion, or any combination thereof.
[0031] In some embodiments, the present disclosure provides a composition comprising a set of primers and / or a set of primers and probes, wherein one or more forward primers, one or more reverse primers, one or more probes or a combination thereof comprise a detectable marker. In some embodiments, wherein the composition comprises one or more detectable markers, and one or more detectable markers may not comprise nucleotides. In some embodiments, the composition comprises one or more detectable markers as a fluorescent moiety. In some embodiments, wherein the composition comprises a detectable marker, and one or more probes comprise the detectable marker. In some embodiments, wherein the composition comprises a probe containing a detectable marker, and the detectable marker comprises a fluorescent moiety. In some embodiments, wherein the composition comprises more than one primer and / or probe, and the primer and / or probe comprise a detectable marker as a fluorescent moiety, and the primer and / or probe may comprise the same fluorescent moiety. In some embodiments, wherein the composition comprises more than one primer and / or probe, and the primer and / or probe comprise a detectable marker as a fluorescent moiety, and the probe may comprise different fluorescent moieties. In some embodiments, where the composition comprises one or more probes comprising a detectable label as a fluorescent moiety, the probes may further comprise one or more quenchers. In some embodiments, where the composition comprises one or more probes comprising a detectable label as a fluorescent moiety, the probes may further comprise more than one quencher molecule, which may be the same molecule, or may be different molecules.
[0032] In some embodiments, the present disclosure provides compositions wherein the active fragment is at least 10 nucleotides in length, at least 11 nucleotides in length, at least 12 nucleotides in length, at least 13 nucleotides in length, at least 14 nucleotides in length, at least 15 nucleotides in length, at least 16 nucleotides in length, at least 17 nucleotides in length, at least 18 nucleotides in length, at least 19 nucleotides in length, at least 20 nucleotides in length, at least 21 nucleotides in length, at least 22 nucleotides in length, at least 23 nucleotides in length, at least 24 nucleotides in length, at least 25 nucleotides in length, at least 26 nucleotides in length, at least 27 nucleotides in length, at least 28 nucleotides in length, or at least 29 nucleotides in length.
[0033] In some embodiments, the present disclosure provides methods comprising contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising one or more regulatory elements and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the target gene, and the second primer comprises a sequence corresponding to or complementary to the regulatory element.
[0034] In some embodiments, the present disclosure provides a method comprising (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising one or more regulatory elements and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the target gene, and the second primer comprises a sequence corresponding to or complementary to the regulatory element; and (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or a fragment thereof; (ii) a second strand comprising: (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence complementary to a portion of the AAV construct or a fragment thereof; or (iii) a combination thereof.
[0035] In some embodiments, the present disclosure provides a method comprising (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising one or more regulatory elements and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the target gene, and the second primer comprises a sequence corresponding to or complementary to the regulatory element; and b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or a fragment thereof; (ii) a second strand comprising: (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence complementary to a portion of the AAV construct or a fragment thereof; or (iii) a combination thereof; and wherein the portion of the AAV construct or a fragment thereof comprises a nucleotide sequence spanning the junction between the regulatory element and the target therapeutic gene.
[0036] In some embodiments, the present disclosure provides methods comprising contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising two or more regulatory elements and a gene of interest, wherein the first primer comprises a sequence corresponding to or complementary to the first regulatory element, and the second primer comprises a sequence corresponding to or complementary to the second regulatory element.
[0037] In some embodiments, the present disclosure provides a method comprising (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising two or more regulatory elements and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the first regulatory element, and the second primer comprises a sequence corresponding to or complementary to the second regulatory element; and (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or a fragment thereof; (ii) a second strand comprising: (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence complementary to a portion of the AAV construct or a fragment thereof; or (iii) a combination thereof.
[0038] In some embodiments, the present disclosure provides a method comprising (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising two or more regulatory elements and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the first regulatory element, and the second primer comprises a sequence corresponding to or complementary to the second regulatory element; and (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or a fragment thereof; (ii) a second strand comprising: (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence complementary to a portion of the AAV construct or a fragment thereof; or (iii) a combination thereof; and wherein the portion of the AAV construct or a fragment thereof comprises a nucleotide sequence spanning the junction between the first regulatory element and the second regulatory element.
[0039] In some embodiments, the present disclosure provides methods comprising contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising a construct sequence, one or more regulatory elements, and a gene of interest, wherein the first primer comprises a sequence corresponding to or complementary to the construct sequence, and the second primer comprises a sequence corresponding to or complementary to the regulatory element.
[0040] In some embodiments, the present disclosure provides a method comprising (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising a construct sequence, one or more regulatory elements, and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the construct sequence, and the second primer comprises a sequence corresponding to or complementary to the regulatory element; and (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or a fragment thereof; (ii) a second strand comprising: (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence complementary to a portion of the AAV construct or a fragment thereof; or (iii) a combination thereof.
[0041] In some embodiments, the present disclosure provides a method comprising (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising a construct sequence, one or more regulatory elements, and a target gene, wherein the first primer comprises a sequence corresponding to or complementary to the construct sequence, and the second primer comprises a sequence corresponding to or complementary to the regulatory element; and (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises: (i) a first strand comprising: (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or a fragment thereof; (ii) a second strand comprising: (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence complementary to a portion of the AAV construct or a fragment thereof; or (iii) a combination thereof, and wherein the portion of the AAV construct or a fragment thereof comprises a nucleotide sequence spanning the junction between the construct sequence and the regulatory element.
[0042] Specifically, this application relates to the following specific implementations:
[0043] 1. A composition comprising a set of primers, wherein the set of primers comprises:
[0044] (a) one or more forward primers, comprising a forward primer having a nucleotide sequence according to SEQ ID NO: 1 or an active fragment thereof; and
[0045] (b) one or more reverse primers, comprising a reverse primer having a nucleotide sequence according to SEQ ID NO: 11 or an active fragment thereof.
[0046] 2. The composition of item 1, further comprising:
[0047] One or more probes comprising a probe having a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof.
[0048] 3. The composition of item 1 or 2, wherein the one or more forward primers, the one or more reverse primers, the one or more probes or a combination thereof are DNA.
[0049] 4. The composition of any one of items 1-3, wherein the one or more forward primers, the one or more reverse primers, the one or more probes, or a combination thereof, comprise a detectable label.
[0050] 5. The composition of item 4, wherein the detectable label does not comprise a nucleotide.
[0051] 6. The composition of item 4 or 5, wherein the detectable label is a fluorescent moiety.
[0052] 7. The composition of any one of items 1-6, wherein the probe comprises a fluorescent moiety.
[0053] 8. The composition of item 7, wherein the probe comprises one or more quenchers.
[0054] 9. The composition of any one of items 1 to 8, wherein the active fragment is
[0055] (a) at least 10 nucleotides in length;
[0056] (b) at least 15 nucleotides in length; or
[0057] (c) at least 20 nucleotides in length.
[0058] 10. The composition of any one of items 1-9, wherein the composition further comprises a sample obtained from a subject to whom a Duchenne muscular dystrophy (DMD) AAV construct has been administered, wherein the DMD AAV construct comprises one or more regulatory elements and a target therapeutic gene, and wherein the sample comprises nucleic acid.
[0059] 11. The composition of item 10, wherein the nucleic acid in the sample comprises a DMD AAV construct or a fragment thereof.
[0060] 12. The composition of item 10 or 11, wherein the one or more regulatory elements comprise an enhancer, a promoter, a poly A signal sequence or a combination thereof.
[0061] 13. The composition of any one of items 10-12, wherein the target therapeutic gene comprises micro-dystrophin.
[0062] 14. The composition of any one of items 10-13, further comprising a plurality of amplicons, wherein each amplicon comprises:
[0063] (a) a first chain comprising:
[0064] (i) a nucleotide sequence corresponding to the forward primer, and
[0065] (ii) a nucleotide sequence corresponding to a portion of a DMD AAV construct or a fragment thereof;
[0066] (b) a second strand comprising:
[0067] (i) the nucleotide sequence of the reverse primer, and
[0068] (ii) a nucleotide sequence that is complementary to a portion of a DMD AAV construct or a fragment thereof; or
[0069] (c) any combination thereof; and
[0070] Wherein the portion of the DMD AAV construct or fragment thereof comprises a nucleotide sequence spanning the junction between two regulatory elements or the junction between a regulatory element and a therapeutic gene of interest.
[0071] 15. The composition of item 14, wherein a probe having a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof is capable of hybridizing with the amplicon.
[0072] 16. The composition of claim 15, wherein the level of probe-amplicon hybridization is detectable.
[0073] 17. The composition of item 15 or 16, wherein the level of probe-amplicon hybridization is quantifiable.
[0074] 18. A method comprising:
[0075] (a) contacting a sample obtained from a subject with a composition according to any one of items 1-9, wherein a DMD AAV construct has been administered to the subject, wherein the DMD AAV construct comprises one or more regulatory elements and a therapeutic gene of interest; and
[0076] (b) amplifying a target sequence to generate a plurality of amplicons, wherein the target sequence is a DMD AAV construct or a fragment thereof, and each amplicon comprises:
[0077] (i) a first chain comprising:
[0078] (1) a nucleotide sequence corresponding to the forward primer, and
[0079] (2) a nucleotide sequence corresponding to a portion of the DMD AAV construct or a fragment thereof;
[0080] (ii) a second strand comprising:
[0081] (1) the nucleotide sequence of the reverse primer, and
[0082] (2) a nucleotide sequence that is complementary to a portion of the DMD AAV construct or a fragment thereof; or
[0083] (iii) any combination thereof; and
[0084] Wherein the portion of the DMD AAV construct or fragment thereof comprises a nucleotide sequence spanning the junction between two regulatory elements or the junction between a regulatory element and a therapeutic gene of interest.
[0085] 19. The method of item 18, wherein the composition comprises a plurality of probes, each probe having a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof.
[0086] 20. The method of item 19, further comprising detecting the level of hybridization between the plurality of probes and the plurality of amplicons.
[0087] 21. The method of item 20, wherein the level of hybridization between the multiple probes and the multiple amplicons indicates the amount of DMD AAV construct in the sample.
[0088] 22. A composition comprising a set of primers, the set of primers comprising:
[0089] (a) one or more forward primers, comprising a forward primer having a nucleotide sequence according to SEQ ID NO: 35 or an active fragment thereof; and
[0090] (b) one or more reverse primers, comprising a reverse primer having a nucleotide sequence according to SEQ ID NO: 45 or an active fragment thereof.
[0091] 23. The composition of item 22, further comprising:
[0092] One or more probes comprising a probe having a nucleotide sequence according to SEQ ID NO: 55 or an active fragment thereof.
[0093] 24. The composition of item 22 or 23, wherein the one or more forward primers, the one or more reverse primers, the one or more probes or a combination thereof are DNA.
[0094] 25. The composition of any one of items 22-24, wherein the one or more forward primers, the one or more reverse primers, the one or more probes, or a combination thereof, comprise a detectable label.
[0095] 26. The composition of claim 25, wherein the detectable label does not comprise a nucleotide.
[0096] 27. The composition of item 25 or 26, wherein the detectable label is a fluorescent moiety.
[0097] 28. The composition of any one of items 22-27, wherein the probe comprises a fluorescent moiety.
[0098] 29. The composition of item 28, wherein the probe comprises one or more quenchers.
[0099] 30. The composition of any one of items 22-29, wherein the active fragment is
[0100] (a) at least 10 nucleotides in length;
[0101] (b) at least 15 nucleotides in length; or
[0102] (c) at least 20 nucleotides in length.
[0103] 31. The composition of any one of items 22-30, wherein the composition further comprises a sample obtained from a subject to whom a hemophilia B (Hem-B) AAV construct has been administered, wherein the Hem-B AAV construct comprises one or more regulatory elements and a target therapeutic gene, and wherein the sample comprises nucleic acid.
[0104] 32. The composition of claim 31, wherein the nucleic acid in the sample comprises a Hem-B AAV construct or a fragment thereof.
[0105] 33. The composition of item 31 or 32, wherein the one or more regulatory elements comprise an enhancer, a promoter, a poly A signal sequence or a combination thereof.
[0106] 34. The composition of any one of items 31-33, wherein the target therapeutic gene comprises Factor IX.
[0107] 35. The composition of any one of items 31-34, wherein the composition further comprises a plurality of amplicons, wherein each amplicon comprises:
[0108] (a) a first chain comprising:
[0109] (i) a nucleotide sequence corresponding to the forward primer, and
[0110] (ii) a nucleotide sequence corresponding to a portion of a Hem-B AAV construct or a fragment thereof;
[0111] (b) a second strand comprising:
[0112] (i) the nucleotide sequence of the reverse primer, and
[0113] (ii) a nucleotide sequence that is complementary to a portion of a Hem-B AAV construct or a fragment thereof; or
[0114] (c) any combination thereof; and
[0115] Wherein the portion of the Hem-B AAV construct or fragment thereof comprises a nucleotide sequence spanning the junction between two regulatory elements or the junction between a regulatory element and a therapeutic gene of interest.
[0116] 36. The composition of item 35, wherein a probe having a nucleotide sequence according to SEQ ID NO: 55 or an active fragment thereof is capable of hybridizing with the amplicon.
[0117] 37. The composition of claim 36, wherein the level of probe-amplicon hybridization is detectable.
[0118] 38. The composition of item 36 or 37, wherein the level of probe-amplicon hybridization is quantifiable.
[0119] 39. A method comprising:
[0120] (a) contacting a sample obtained from a subject with a composition according to any one of items 43 to 51,
[0121] wherein a Hem-B AAV construct has been administered to the subject, wherein the Hem-B AAV construct comprises one or more regulatory elements and a therapeutic gene of interest; and
[0122] (b) amplifying a target sequence to generate a plurality of amplicons, wherein the target sequence is a Hem-B AAV construct or a fragment thereof, and each amplicon comprises:
[0123] (i) a first chain comprising:
[0124] (1) a nucleotide sequence corresponding to the forward primer, and
[0125] (2) a nucleotide sequence corresponding to a portion of a strand of a Hem-B AAV construct or a fragment thereof;
[0126] (ii) a second strand comprising:
[0127] (1) the nucleotide sequence of the reverse primer, and
[0128] (2) a nucleotide sequence that is complementary to a portion of a strand of a Hem-B AAV construct or a fragment thereof; or
[0129] (iii) any combination thereof; and
[0130] Wherein the portion of the Hem-B AAV construct or fragment thereof comprises a nucleotide sequence spanning the junction between two regulatory elements or the junction between a regulatory element and a therapeutic gene of interest.
[0131] 40. The method of item 39, wherein the composition comprises a plurality of probes, each probe having a nucleotide sequence according to SEQ ID NO: 55 or an active fragment thereof.
[0132] 41. The method of item 40, further comprising detecting the level of hybridization between the plurality of probes and the plurality of amplicons.
[0133] 42. The method of item 41, wherein the level of hybridization between the multiple probes and the multiple amplicons indicates the amount of DMD AAV construct in the sample.
[0134] 43. A method comprising:
[0135] (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising one or more regulatory elements and a gene of interest, wherein the first primer comprises a sequence corresponding to or complementary to the gene of interest, and the second primer comprises a sequence corresponding to or complementary to the regulatory element; and
[0136] (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises:
[0137] (i) a first chain comprising:
[0138] (1) a nucleotide sequence corresponding to the forward primer, and
[0139] (2) a nucleotide sequence corresponding to a portion of an AAV construct or a fragment thereof;
[0140] (ii) a second strand comprising:
[0141] (1) the nucleotide sequence of the reverse primer, and
[0142] (2) a nucleotide sequence that is complementary to a portion of an AAV construct or a fragment thereof; or
[0143] (iii) any combination thereof;
[0144] Wherein the portion of the AAV construct or fragment thereof comprises a nucleotide sequence spanning the junction between the regulatory element and the therapeutic gene of interest.
[0145] 44. A method comprising:
[0146] (a) contacting a sample obtained from a subject with a composition comprising a first primer and a second primer, wherein the subject has previously been administered an AAV construct comprising two or more regulatory elements and a gene of interest, wherein the first primer comprises a sequence corresponding to or complementary to the first regulatory element and the second primer comprises a sequence corresponding to or complementary to the second regulatory element; and
[0147] (b) performing a polymerase chain reaction to generate a plurality of amplicons, wherein the target sequence is an AAV construct or a fragment thereof, and each amplicon comprises:
[0148] (i) a first chain comprising:
[0149] (1) a nucleotide sequence corresponding to the forward primer, and
[0150] (2) a nucleotide sequence corresponding to a portion of an AAV construct or a fragment thereof;
[0151] (ii) a second strand comprising:
[0152] (1) the nucleotide sequence of the reverse primer, and
[0153] (2) a nucleotide sequence that is complementary to a portion of an AAV construct or a fragment thereof; or
[0154] (iii) any combination thereof;
[0155] Wherein the portion of the AAV construct or fragment thereof comprises a nucleotide sequence spanning the junction between the first regulatory element and the second regulatory element.
[0156] definition
[0157] The scope of the present disclosure is defined by the claims appended hereto and is not limited by certain embodiments described herein. Those skilled in the art who read this specification will recognize various modifications that may be equivalent to such described embodiments or otherwise within the scope of the claims. In general, unless otherwise clearly indicated, the terms used herein are understood in the art according to their meanings. The following provides clear definitions of certain terms; throughout the specification, the meanings of these and other terms in specific cases will be clear to those skilled in the art from the context.
[0158] The use of sequential terms such as "first", "second", "third" in the claims to modify claim elements does not itself imply any priority, precedence or order of one claim element relative to another claim element or action in method, but is merely used as a mark to distinguish one claim element with a specific name from another element with the same name (but used to use sequential terms) to distinguish the time sequence of the claim elements.
[0159] As used herein, the articles "a" and "an" should be understood to include plural references unless clearly indicated to the contrary. If one, more than one or all of the group members are present in a given product or process, used in a given product or process, or otherwise related to a given product or process, a claim or description including "or" between one or more members of the group is considered to be satisfied, unless otherwise indicated to be contrary to the context or otherwise obvious from the context. In some embodiments, exactly one member of the group is present in a given product or process, used in a given product or process, or otherwise related to a given product or process. In some embodiments, more than one or all of the group members are present in a given product or process, used in a given product or process, or otherwise related to a given product or process. It should be understood that the present disclosure encompasses all variations, combinations, and permutations, wherein one or more limitations, elements, clauses, descriptive terms, etc. from one or more of the listed claims are introduced into another claim subordinate to the same basic claim (or when relevant, any other claim), unless otherwise indicated or unless it is obvious to a person of ordinary skill in the art that a contradiction or inconsistency occurs. Where elements are presented as a list (e.g., in Markush groups or similar format), it is understood that each subgroup of the elements is also disclosed and any element may be removed from the group. It is understood that, in general, where an embodiment or aspect is referred to as "comprising" a particular element, feature, etc., certain embodiments or aspects are "consisting of" or "consisting essentially of" such elements, features, etc. For purposes of simplicity, which embodiments are not specifically described herein in so many words in each case. It is also understood that any embodiment or aspect may be explicitly excluded from the claims, regardless of whether a specific exclusion is recorded in the specification.
[0160] Throughout the specification, when any polynucleotide or polypeptide is represented by a sequence of letters (e.g., A, C, G, T and U, which represent adenosine, cytidine, guanosine, thymidine and uridine, respectively), such nucleotides or peptides are presented in order from left to right from 5' to 3' or N-terminus to C-terminus.
[0161] Administration: As used herein, the term "administering" generally refers to applying a composition to a subject or system to achieve delivery of an agent to a subject or system. In some embodiments, the agent is a composition or is contained in a composition; in some embodiments, the agent is generated by the metabolism of the composition or one or more components thereof. One of ordinary skill in the art will recognize that various routes applicable to subjects, such as humans, can be used under appropriate circumstances. For example, in some embodiments, administration can be systemic or local. In some embodiments, systemic administration can be intravenous. In some embodiments, administration can be local. Local administration can involve delivery to the cochlear perilymph via, for example, injection through the round window membrane or injection into the scala tympani, through the endolymph, perilymph and / or tube stoma post-endolymphatic mid-scala injection. In some embodiments, administration can involve only a single dose. In some embodiments, administration can involve the application of a fixed number of doses. In some embodiments, administration can involve intermittent (e.g., multiple doses separated in time) and / or periodic (e.g., a single dose separated by a common time period) administration. In some embodiments, administration can involve continuous administration (e.g., perfusion) for at least a selected time period.
[0162] Allele: As used herein, the term "allele" refers to one of two or more existing genetic variants of a particular polymorphic genomic locus.
[0163] Amelioration: As used herein, the term "amelioration" refers to the prevention, reduction, or alleviation of a subject's condition, or an improvement in a subject's condition. Amelioration may include but does not require complete recovery or complete prevention of a disease, disorder, or condition.
[0164] Amino acid: In its broadest sense, as used herein, the term "amino acid" refers to any compound and / or substance that can be incorporated into a polypeptide chain, for example, by forming one or more peptide bonds. In some embodiments, an amino acid has a general structure, for example, H2N-C(H)(R)-COOH. In some embodiments, an amino acid is a naturally occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than a standard amino acid, whether it is prepared synthetically or obtained from a natural source. In some embodiments, amino acids, including carboxyl-terminal and / or amino-terminal amino acids in a polypeptide, may contain structural modifications compared to the general structure shown above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., of an amino group, a carboxylic acid group, one or more protons, and / or hydroxyl groups) compared to the general structure. In some embodiments, compared to a polypeptide containing otherwise identical unmodified amino acids, this modification can for example change the circulatory half-life of the polypeptide containing the modified amino acids. In some embodiments, compared to a polypeptide containing otherwise identical unmodified amino acids, this modification does not significantly change the associated activity of the polypeptide containing the modified amino acids.
[0165] Amplicon: As used herein, the term "amplicon" refers to a polynucleotide produced by an amplification (e.g., polymerase chain reaction (PCR)) or replication process. An amplicon may also be referred to as a "PCR product". An amplicon may be specific for a particular polynucleotide construct, oligonucleotide primer pair, and / or oligonucleotide probe. For example, an "amplicon" may refer to (a) a first strand comprising (i) a nucleotide sequence corresponding to a forward primer and (ii) a nucleotide sequence corresponding to a portion of a strand of a construct or a fragment thereof, and / or (b) a second strand comprising: (i) a nucleotide sequence of a reverse primer, and (ii) a nucleotide sequence complementary to a portion of a strand of a construct or a fragment thereof. In some embodiments, "amplicon" can refer to (a) a first strand comprising (i) a nucleotide sequence corresponding to a forward primer, (ii) a nucleotide sequence corresponding to a portion of a strand of a construct or a fragment thereof, and (iii) a nucleotide sequence complementary to a reverse primer; and / or (b) a second strand comprising: (i) a nucleotide sequence of a reverse primer, (ii) a nucleotide sequence complementary to a portion of a strand of a construct or a fragment thereof, and (iii) a nucleotide sequence complementary to a forward primer.
[0166] Approximately or about: As used herein, the term "approximately" or "about" may be applied to one or more target values, including values similar to a specified reference value. In some embodiments, the term "approximately" or "about" refers to a range of values that fall within ±10% (greater or less than) of a specified reference value, unless otherwise specified or otherwise apparent from the context (unless such a number would exceed 100% of the possible value). For example, in some embodiments, the term "approximately" or "about" may encompass a range of values within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% 1% or less of a reference value.
[0167] Related: As used herein, the term "related" describes two events or entities as being "related" to each other if the presence, level, and / or form of one is related to the presence, level, and / or form of the other. For example, if the presence, level, and / or form of a particular entity (e.g., a polypeptide, a genetic signature, a metabolite, a microorganism, etc.) is associated with the occurrence of a disease, disorder, or condition (e.g., in a related population) and / or susceptibility to a disease, disorder, or condition (e.g., in a related population), it is considered to be associated with a particular disease, disorder, or condition. In some embodiments, two or more entities are physically "associated" with each other if they interact directly or indirectly so that they are in physical proximity and / or remain in physical proximity to each other. In some embodiments, two or more entities that are physically associated with each other are covalently linked to each other; in some embodiments, two or more entities that are physically associated with each other are not covalently linked to each other but are non-covalently associated, such as by means of hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof.
[0168] Biologically active: As used herein, the term "biologically active" refers to an observable biological effect or result achieved by a target agent or entity. For example, in some embodiments, a specific binding interaction is a biological activity. In some embodiments, modulation (e.g., induction, enhancement, or inhibition) of a biological pathway or event is a biological activity. In some embodiments, the presence or extent of a biological activity is assessed by detecting a direct or indirect product produced by a target biological pathway or event.
[0169] Characteristic part: As used herein, the term "characteristic part" refers in the broadest sense to a part of a substance whose presence (or absence) is associated with the presence (or absence) of a particular characteristic, property, or activity of the substance. In some embodiments, the characteristic part of a substance is a part found in a given substance and related substances that share a particular characteristic, property, or activity, but not found in those that do not share a particular characteristic, property, or activity. In some embodiments, the characteristic part shares at least one functional feature with the complete substance. For example, in some embodiments, the "characteristic part" of a protein or polypeptide is a "characteristic part" of a protein or polypeptide containing a continuous stretch of amino acids or a collection of continuous stretches of amino acids (which together are the characteristics of the protein or polypeptide). In some embodiments, each such continuous stretch typically contains at least 2, 5, 10, 15, 20, 50 or more amino acids. In general, a characteristic part of a substance (e.g., a protein, an antibody, etc.) is a part that shares at least one functional feature with the relevant complete substance in addition to the sequence and / or structural identity specified above. In some embodiments, the characteristic part can be biologically active.
[0170] Characteristic sequence: As used herein, the term "characteristic sequence" is a sequence that is found in all members of a family of polypeptides or nucleic acids, and thus can be used by one of ordinary skill in the art to define a family of members.
[0171] Characteristic sequence element: As used herein, the phrase "characteristic sequence element" refers to a sequence element found in a polymer (e.g., in a polypeptide or nucleic acid) that represents a characteristic portion of the polymer. In some embodiments, the presence of a characteristic sequence element is associated with the presence or level of a specific activity or characteristic of a polymer. In some embodiments, the presence (or absence) of a characteristic sequence element defines a specific polymer as a member (or not a member) of a specific family or group of such polymers. Characteristic sequence elements generally comprise at least two monomers (e.g., amino acids or nucleotides). In some embodiments, characteristic sequence elements include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50 or more monomers (e.g., continuously connected monomers). In some embodiments, characteristic sequence elements include at least the first and second continuous monomer stretches separated by one or more spacers, and the length of the spacer may or may not vary in the polymer sharing the sequence element.
[0172] Cleavage: As used herein, the term "cleavage" refers to the generation of a break in DNA. For example, in some embodiments, cleavage can refer to a single-strand break or a double-strand break, depending on the type of nuclease that can be used to cause such a break.
[0173] Combination therapy: As used herein, the term "combination therapy" refers to those situations in which a subject is exposed to two or more treatment regimens (e.g., two or more therapeutic agents) simultaneously. In some embodiments, two or more agents may be administered simultaneously. In some embodiments, two or more agents may be administered sequentially. In some embodiments, two or more agents may be administered in overlapping dosing regimens.
[0174] Comparable: As used herein, the term "comparable" refers to two or more agents, entities, situations, condition sets, subjects, populations, etc., which may be different from each other, but are similar enough to allow comparisons between them, so that those skilled in the art will understand that conclusions can be reasonably drawn based on the observed differences or similarities. In some embodiments, the collection of comparable agents, entities, situations, condition sets, subjects, populations, etc. is characterized by a plurality of substantially identical features and one or a small number of different features. One of ordinary skill in the art will understand, in context, what degree of identity is required for two or more such agents, entities, situations, condition sets, subjects, populations, etc. to be considered comparable in any given case. For example, one of ordinary skill in the art will understand that sets of agents, entities, situations, conditions, subjects, populations, etc., are comparable to one another when characterized by a sufficient number and type of substantially identical characteristics to warrant a reasonable conclusion that differences in results or observed phenomena obtained under or with different sets of environments, stimuli, agents, entities, situations, conditions, subjects, populations, etc., are caused by or indicated by changes in different those characteristics.
[0175] Construct: As used herein, the term "construct" refers to a composition comprising a polynucleotide capable of carrying at least one heterologous polynucleotide. In some embodiments, the construct can be a plasmid, a transposon, a cosmid, an artificial chromosome (e.g., a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC), or a P1-derived artificial chromosome (PAC)) or a viral construct, as well as any Plasmid. For example, the construct may include sufficient cis-acting elements for expression; other expression elements may be provided by host primate cells or in an in vitro expression system. The construct may include any genetic element (e.g., a plasmid, a transposon, a cosmid, an artificial chromosome, or a viral construct, etc.) that is capable of replication when associated with appropriate control elements. Thus, in some embodiments, a "construct" may include a clone and / or expression construct and / or a viral construct (e.g., an adeno-associated virus (AAV) construct, an adenoviral construct, a lentiviral construct, or a retroviral construct).
[0176] Conservative: As used herein, the term "conservative" refers to an example of describing a conservative amino acid substitution, including substitution of an amino acid residue with another amino acid residue having a side chain R group of similar chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions do not substantially change the target functional properties of a protein, such as the ability of a receptor to bind a ligand. Examples of groups of amino acids having side chains with similar chemical properties include: aliphatic side chains, such as glycine (Gly, G), alanine (Ala, A), valine (Val, V), leucine (Leu, L), and isoleucine (Ile, I); aliphatic-hydroxy side chains, such as serine (Ser, S) and threonine (Thr, T); amide-containing side chains, such as asparagine (Asn, N) and glutamine (Gln, Q); aromatic side chains, such as phenylalanine (Phe, F), tyrosine (Tyr, Y), and tryptophan (Trp, W); basic side chains, such as lysine (Lys, K), arginine (Arg, R), and histidine (His, H); acidic side chains, such as aspartic acid (Asp, D) and glutamic acid (Glu, E); and sulfur-containing side chains, such as cysteine (Cys, C) and methionine (Met, M). Conservative amino acid substitutions include, for example, valine / leucine / isoleucine (Val / Leu / Ile, V / L / I), phenylalanine / tyrosine (Phe / Tyr, F / Y), lysine / arginine (Lys / Arg, K / R), alanine / valine (Ala / Val, A / V), glutamic acid / aspartic acid (Glu / Asp, E / D) and asparagine / glutamine (Asn / Gln, N / Q). In some embodiments, conservative amino acid substitutions can be substitutions of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis. In some embodiments, conservative substitutions with positive values in the PAM250 log-likelihood matrix disclosed in Gonnet, GH et al., 1992, Science 256: 1443-1445 (which is incorporated herein by reference in its entirety) are performed. In some embodiments, substitutions are moderately conservative substitutions, wherein the substitutions have non-negative values in the PAM250 log-likelihood matrix. Those skilled in the art will appreciate that changes (e.g., substitutions, additions, deletions, etc.) to amino acids that are not conserved between the same proteins from different species are unlikely to have an effect on the function of the protein, and therefore, these amino acids should be selected for mutation. Amino acids that are conserved between the same proteins from different species should not be changed (e.g., deleted, added, substituted, etc.) because these mutations are more likely to result in changes in protein function.
[0177]
[0178] Control: As used herein, the term "control" refers to the meaning of "control" as a standard for its comparison results understood in the art. Typically, controls are used to strengthen the integrity of an experiment by isolating variables so that conclusions can be drawn about such variables. In some embodiments, a control is a reaction or assay performed simultaneously with a test reaction or assay to provide a comparator. For example, in one experiment, a "test" (i.e., the variable tested) is applied. In a second experiment, a "control" is not applied to the variable tested. In some embodiments, a control is a historical control (e.g., a previously performed test or assay or a previously known amount or result historical control). In some embodiments, a control is or comprises a printed or otherwise preserved record. In some embodiments, a control is a positive control. In some embodiments, a control is a negative control.
[0179] Determine, measure, assess, evaluate, determine, and analyze: As used herein, the terms "determine," "measure," "assess," "evaluate," "determine," and "analyze" are used interchangeably to refer to any form of measurement, and include determining whether an element is present. These terms include quantitative and / or qualitative determinations. Determinations can be relative or absolute. For example, in some embodiments, "determining the presence of" can be determining the amount of something present and / or determining whether it is present.
[0180] Editing: As used herein, the term "editing", "editing" or "edited" refers to a method of changing the nucleic acid sequence of a polynucleotide (e.g., a wild-type naturally occurring nucleic acid sequence or a mutated naturally occurring sequence) by selectively deleting a specific nucleic acid sequence (e.g., a genomic target sequence), by using an exogenous nucleic acid sequence to give specificity to a new sequence, or by replacing a nucleic acid sequence with an exogenous nucleic acid sequence. In some embodiments, such a specific genomic target includes, but may not be limited to, a chromosomal region, mitochondrial DNA, a gene, a promoter, an open reading frame, or any nucleic acid sequence.
[0181] Engineered: Generally speaking, as used herein, the term "engineered" refers to aspects that have been artificially manipulated. For example, if a cell or organism is manipulated so as to change its genetic information (introducing new genetic material that did not previously exist, for example, by transformation, conjugation, somatic cell hybridization, transfection, transduction or other mechanisms, or changing or removing previously existing genetic material, for example, by substitution or deletion mutations, or by conjugation schemes), the cell or organism is considered to be "engineered". As commonly practiced and understood by those skilled in the art, the progeny of engineered polynucleotides or cells are still generally referred to as "engineered", even if the actual operation is performed on the previous entity.
[0182] Excipient: As used herein, the term "excipient" refers to an inactive (e.g., non-therapeutic) agent that can be included in a pharmaceutical composition, for example, to provide or contribute to a desired consistency or stabilizing effect. In some embodiments, suitable pharmaceutical excipients can include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc.
[0183] Expression: As used herein, the term "expression" of a nucleic acid sequence refers to the generation of any gene product (e.g., transcript, e.g., mRNA, e.g., polypeptide, etc.) from the nucleic acid sequence. In some embodiments, the gene product may be a transcript. In some embodiments, the gene product may be a polypeptide. In some embodiments, expression of a nucleic acid sequence involves one or more of the following: (1) generating an RNA template from a DNA sequence (e.g., by transcription); (2) processing the RNA transcript (e.g., by splicing, editing, 5' cap formation and / or 3' end formation); (3) translating the RNA into a polypeptide or protein; and / or (4) post-translationally modifying the polypeptide or protein.
[0184] Functionality: As used herein, the term "functional" describes something that exists in a form in which it exhibits the properties and / or activities for which it is characterized. For example, in some embodiments, a "functional" biomolecule is a form of a biomolecule in which it exhibits the properties and / or activities for which it is characterized. In some such embodiments, a functional biomolecule is characterized relative to another non-functional biomolecule in that the "non-functional" form does not exhibit the same or equivalent properties and / or activities as the "functional" molecule. A biomolecule may have one function, two functions (i.e., bifunctional), or multiple functions (i.e., multifunctional).
[0185] Gene: As used herein, the term "gene" refers to a DNA sequence in a chromosome that encodes a gene product (e.g., an RNA product, such as a polypeptide product). In some embodiments, a gene includes a coding sequence (i.e., a sequence encoding a specific product). In some embodiments, a gene includes a non-coding sequence. In some specific embodiments, a gene may include both coding (e.g., exons) and non-coding (e.g., introns) sequences. In some embodiments, a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and / or intron sequences, for example, which may control or affect one or more aspects of gene expression (e.g., cell type-specific expression, inducible expression, etc.). As used herein, the term "gene" generally refers to a nucleic acid portion encoding a polypeptide or a fragment thereof; the term may optionally encompass regulatory sequences, which will be clear from the context to a person of ordinary skill in the art. This definition is not intended to exclude the application of the term "gene" to non-protein coding expression units, but to clarify that in most cases, the term as used in this document refers to a nucleic acid encoding a polypeptide. In some embodiments, a gene may encode a polypeptide, but the polypeptide may not be functional, for example, a gene variant may encode a polypeptide that does not function in the same manner or at all relative to the wild-type gene. In some embodiments, a gene may encode a transcript, which in some embodiments may have toxicity above a threshold level. In some embodiments, a gene may encode a polypeptide, but the polypeptide may not be functional and / or may have toxicity above a threshold level.
[0186] Gene therapy: As used herein, the term "gene therapy" means a therapy involving the administration of a biological or synthetically produced composition to a subject that (a) delivers a nucleic acid, such as DNA or RNA, in vivo or ex vivo and results in transient or stable expression of an RNA sequence and / or protein encoded by the delivered DNA or RNA, which expression can be episomal or from a nucleic acid that has integrated into the genome, (b) delivers mRNA and results in the expression of a protein from the delivered mRNA, or (c) delivers any gene editing or base editing system, including but not limited to TALENS, Megatal, zinc finger proteins, CRISPR / Cas9 or other Cas-based systems, the delivery of which results in (1) the introduction of epigenetic modifications to chromosomal sequence elements that alter the transcription of genes associated with the chromosomal sequence elements, or (2) deletion, insertion or modification of DNA or RNA sequences in the genome or transcriptome.
[0187] Genome editing system: As used herein, the term "genome editing system" refers to any system with DNA editing activity. Among other things, DNA editing activity can include deletion, replacement or insertion of a DNA sequence in a genome. In some embodiments, the genome editing system comprises RNA-guided DNA editing activity. In some embodiments, the genome editing system of the present disclosure includes more than one component. In some embodiments, the genome editing system includes at least two components adapted from the naturally occurring CRISPR system: guide RNA (gRNA) and RNA-guided nuclease. In certain embodiments, these two components form a complex that is able to associate with a specific nucleic acid sequence and edit the DNA in or around the nucleic acid sequence, such as by producing one or more of a single-strand break (SSB or nick), a double-strand break (DSB) and / or a point mutation. In some embodiments, the genome editing system of the present disclosure lacks a component with cutting activity but maintains a component with DNA binding activity. In some such embodiments, the genome editing system of the present disclosure includes a component that functions as an inhibitor of DNA activity (e.g., transcription, translation, etc.). In some embodiments, the genome editing system of the present disclosure includes a component fused to a regulator to regulate target DNA expression.
[0188] Genome modification: As used herein, the term "genome modification" refers to a change made in a genomic region of a cell that permanently changes the genome (e.g., an endogenous genome) of the cell. In some embodiments, such changes are in vitro, ex vivo, or in vivo. In some embodiments, each cell in a living organism is modified. In some embodiments, only a specific cell group (such as, for example, in a specific organ) is modified. For example, in some embodiments, the genome is modified by deletion, substitution, or addition of one or more nucleotides from one or more genomic regions. In some embodiments, genome modification is performed in stem cells or undifferentiated cells. In some such embodiments, relative to the parental genome before modification, the offspring of the genome-modified cell or organism will also be genome-modified. In some embodiments, genome modification is performed to mature or post-mitotic cells so that offspring will not be generated, and therefore, there is no genome modification for reproduction except in specific cells.
[0189] Heterologous: As used herein, the term "heterologous" can be used with respect to one or more regions of a particular molecule compared to another region and / or another molecule. For example, in some embodiments, heterologous polypeptide domains refer to the fact that the polypeptide domains do not naturally occur together (e.g., in the same polypeptide). For example, in an artificially generated fusion protein, a polypeptide domain from one polypeptide can be fused to a polypeptide domain from a different polypeptide. In such a fusion protein, the two polypeptide domains would be considered "heterologous" to each other because they do not naturally occur together.
[0190] Identity: As used herein, the term "identity" refers to the overall correlation between polymeric molecules, such as nucleic acid molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules. In some embodiments, if the sequence of a polymer molecule has at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identity, it is considered to be "substantially identical" to each other. The calculation of the percentage identity of two nucleic acid or polypeptide sequences, for example, can be by aligning the two sequences for optimal comparison purposes (e.g., spaces can be introduced in one or both of the first and second sequences for optimal alignment, and different sequences can be ignored for comparison purposes). In some embodiments, the length of the sequence compared for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or substantially 100% of the length of the reference sequence; then the nucleotides at the corresponding positions are compared. When the position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, the two molecules (i.e., the first and second) are identical at that position. The percentage identity between the two sequences is a function of the number of identical positions shared by the two sequences being compared, which takes into account the number of spaces and the length of each space, and the spaces need to be introduced for the best alignment of the two sequences. Mathematical algorithms can be used to complete the comparison of sequences and the determination of the percentage identity between the two sequences. For example, the percentage identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17, which is incorporated herein by reference in its entirety), which has been incorporated into the ALIGN program (version 2.0). In some embodiments, nucleic acid sequence comparisons performed with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
[0191] Improve, increase, enhance, inhibit or reduce: As used herein, the terms "improve", "increase", "enhance", "inhibit", "reduce" or their grammatical equivalents indicate values relative to a baseline or other reference measurement. In some embodiments, a value is a statistically significant difference from a baseline or other reference measurement. In some embodiments, an appropriate reference measurement may be or include a measurement in a specific system (e.g., in a single individual) under other comparable conditions in which a specific agent or treatment (e.g., before and / or after) is absent or present, or in the presence of an appropriate comparable reference agent. In some embodiments, an appropriate reference measurement may be or include a measurement in a comparable system that is known or expected to respond in a specific manner in the presence of a relevant agent or treatment. In some embodiments, an appropriate reference is a negative reference; in some embodiments, an appropriate reference is a positive reference.
[0192] Modulate: As used herein, the term "modulate" means mediating a detectable increase or decrease in the level of a response in a subject compared to the level of the response in a subject in the absence of the treatment or compound, and / or compared to the level of the response in an otherwise identical but untreated subject. The term encompasses perturbing and / or influencing a natural signal or response, thereby mediating a beneficial therapeutic response in a subject, preferably a human.
[0193] Nucleic acid: As used herein, the term "nucleic acid" in its broadest sense refers to any compound and / or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, nucleic acids are compounds and / or substances that are or can be incorporated into an oligonucleotide chain via a phosphodiester bond. As will be clear from the context, in some embodiments, "nucleic acid" refers to a single nucleic acid residue (e.g., nucleotide and / or nucleoside); in some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising a single nucleic acid residue. In some embodiments, "nucleic acid" is or comprises RNA; in some embodiments, "nucleic acid" is or comprises DNA. In some embodiments, nucleic acid is one or more natural nucleic acid residues, comprises one or more natural nucleic acid residues, or consists of one or more natural nucleic acid residues. In some embodiments, nucleic acid is one or more nucleic acid analogs, comprises one or more nucleic acid analogs, or consists of one or more nucleic acid analogs. In some embodiments, nucleic acid analogs differ from nucleic acids in that they do not utilize a phosphodiester backbone. Alternatively or in addition, in some embodiments, nucleic acids have one or more phosphorothioate and / or 5'-N-phosphoramidite bonds instead of phosphodiester bonds. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine).In some embodiments, the nucleic acid is one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deaza adenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, 2-thiocytidine, methylated bases, intervening bases, and combinations thereof), comprising one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine , C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intervening bases, and combinations thereof) or one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5- In some embodiments, the nucleic acid comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to those in natural nucleic acids. In some embodiments, the nucleic acid has a nucleotide sequence encoding a functional gene product such as an RNA or protein. In some embodiments, the nucleic acid comprises one or more introns. In some embodiments, the nucleic acid is prepared by one or more of isolation from a natural source, by enzymatic synthesis (in vivo or in vitro) based on polymerization of a complementary template, propagation in a recombinant cell or system, and chemical synthesis.In some embodiments, the nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more residues in length. In some embodiments, the nucleic acid is partially or entirely single-stranded; in some embodiments, the nucleic acid is partially or entirely double-stranded. In some embodiments, the nucleic acid has a nucleotide sequence comprising at least one element that encodes a polypeptide or is complementary to a sequence encoding a polypeptide. In some embodiments, the nucleic acid has enzymatic activity.
[0194] Operably connected: As used herein, refers to a parallel relationship, wherein the components are in a relationship that allows them to function in the manner they are intended. A control element that is "operably connected" to a functional element is associated in such a way that expression and / or activity of the functional element is achieved under conditions compatible with the control element. In some embodiments, an "operably connected" control element is adjacent to a target coding element (e.g., covalently linked); in some embodiments, the control element acts in trans with the target functional element or otherwise acts on the target functional element. In some embodiments, "operably connected" refers to a functional connection between a regulatory sequence and a heterologous nucleic acid sequence, resulting in expression of the latter. For example, when a first nucleic acid sequence is in a functional relationship with a second nucleic acid sequence, the first nucleic acid sequence is operably connected to the second nucleic acid sequence. In some embodiments, for example, a functional connection may include transcriptional control. For example, if a promoter affects the transcription or expression of a coding sequence, the promoter is operably connected to the coding sequence. Operably connected DNA sequences may be continuous with each other, and, for example, in the case where two protein coding regions must be connected, they are located in the same reading frame.
[0195] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to a composition in which an active agent is formulated with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in an amount suitable for a unit dose administered in a treatment regimen, and when administered to a relevant population, the treatment regimen shows a statistically significant probability of achieving a predetermined therapeutic effect. In some embodiments, the pharmaceutical composition can be specially formulated for administration in solid or liquid form, including those suitable for, for example, administration, such as injectable preparations, such as aqueous or non-aqueous solutions or suspensions or drops designed for injection into the ear canal. In some embodiments, the pharmaceutical composition can be formulated for administration via injection in a specific organ or compartment (e.g., directly into the ear) or systemically (e.g., intravenously). In some embodiments, the preparation can be or include an infusion (aqueous or non-aqueous solution or suspension), a tablet, a bolus, a powder, a granule, a paste, a capsule, a powder, etc. In some embodiments, the active agent can be or include an isolated, purified or pure compound.
[0196] Pharmaceutically acceptable: As used herein, the term "pharmaceutically acceptable", for example, as used with respect to a carrier, diluent or excipient used to formulate a pharmaceutical composition as disclosed herein, means that the carrier, diluent, or excipient is compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
[0197] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or vehicle that participates in carrying or transporting the subject compound from one organ or part of the body to another, such as a liquid or solid filler, diluent, rejuvenator and or solvent encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; pH buffered solutions; polyesters, polycarbonates, and / or polyanhydrides; and other nontoxic compatible substances used in pharmaceutical formulations.
[0198] Polypeptide: As used herein, the term "polypeptide" refers to any polymer chain of residues (e.g., amino acids) that are usually linked by peptide bonds. In some embodiments, the polypeptide has a naturally occurring amino acid sequence. In some embodiments, the polypeptide has an amino acid sequence that does not exist in nature. In some embodiments, the polypeptide has an engineered amino acid sequence because it is designed and / or produced by artificial action. In some embodiments, the polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both. In some embodiments, the polypeptide may include one or more side groups or other modifications, for example, at the N-terminus of the polypeptide, at the C-terminus of the polypeptide, or any combination thereof, modified or attached to one or more amino acid side chains. In some embodiments, such side groups or modifications may be acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, the polypeptide may contain L-amino acids, D-amino acids, or both, and may contain any of various amino acid modifications or analogs known in the art. In some embodiments, useful modifications may be or include, for example, terminal acetylation, amidation, methylation, etc. In some embodiments, the protein may contain natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, the protein is an antibody, an antibody fragment, a biologically active portion thereof, and / or a characteristic portion thereof.
[0199] Polynucleotide: As used herein, the term "polynucleotide" refers to any polymeric chain of nucleic acid. In some embodiments, the polynucleotide is or comprises RNA; in some embodiments, the polynucleotide is or comprises DNA. In some embodiments, the polynucleotide is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, the polynucleotide is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, the polynucleotide is different from nucleic acid in that it does not utilize a phosphodiester backbone. Alternatively or in addition, in some embodiments, the polynucleotide has one or more phosphorothioate and / or 5'-N-phosphoramidite bonds instead of phosphodiester bonds. In some embodiments, a polynucleotide is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine).In some embodiments, the polynucleotide is one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7- deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, 2-thiocytidine, methylated bases, intervening bases, and combinations thereof), comprising one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine uridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intervening bases, and combinations thereof) or one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, In some embodiments, the polynucleotides include 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intervening bases, and combinations thereof. In some embodiments, the polynucleotides include one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to those in natural nucleic acids. In some embodiments, the polynucleotides have nucleotide sequences encoding functional gene products such as RNA or proteins. In some embodiments, the polynucleotides include one or more introns. In some embodiments, a polynucleotide is prepared by one or more of isolation from a natural source, by enzymatic synthesis (in vivo or in vitro) based on polymerization of a complementary template, propagation in a recombinant cell or system, and chemical synthesis.In some embodiments, the polynucleotide is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more residues in length. In some embodiments, the polynucleotide is partially or entirely single-stranded; in some embodiments, the polynucleotide is partially or entirely double-stranded. In some embodiments, the polynucleotide has a nucleotide sequence comprising at least one element that encodes a polypeptide or is the complement of a sequence that encodes a polypeptide. In some embodiments, the polynucleotide has enzymatic activity.
[0200] Protein: As used herein, the term "protein" refers to a polypeptide (i.e., a string of at least two amino acids linked to each other by peptide bonds). Proteins may include portions other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and / or may be processed or modified in other ways. One of ordinary skill in the art will appreciate that a "protein" may be a complete polypeptide chain (with or without a signal sequence) as produced by a cell, or may be a characteristic portion thereof. One of ordinary skill will appreciate that a protein may sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or by other means.
[0201] Recombinant: As used herein, the term "recombinant" is intended to refer to a polypeptide designed, engineered, prepared, expressed, produced, manufactured and / or isolated by recombinant means, such as a polypeptide expressed using a recombinant expression construct transfected into a host cell; a polypeptide isolated from a recombinant combinatorial human polypeptide library; a polypeptide isolated from an animal (e.g., mouse, rabbit, sheep, fish, etc.) that is transgenic for or has been manipulated to express one or more genes or genomic components that encode the polypeptide or one or more components, parts, elements or domains thereof and / or direct the expression of the polypeptide or one or more components, parts, elements or domains thereof; and / or a polypeptide prepared, expressed, produced or isolated by any other means involving splicing or ligating selected nucleic acid sequence elements to one another, chemically synthesizing selected sequence elements, and / or otherwise generating a nucleic acid that encodes and / or directs the expression of a polypeptide or one or more components, parts, elements or domains thereof. In some embodiments, one or more of such selected sequence elements are found in nature. In some embodiments, one or more of such selected sequence elements are designed on a computer chip. In some embodiments, one or more such selected sequence elements are from mutagenesis (e.g., in vivo or in vitro) of known sequence elements, e.g., from natural or synthetic sources, such as, for example, in the germline of a target source organism (e.g., people, mice, etc.).
[0202] Reference: As used herein, the term "reference" describes a standard or control relative to which a comparison is made. For example, in some embodiments, a target agent, animal, individual, population, sample, sequence, or value is compared to a reference or control agent, animal, individual, population, sample, sequence, or value. In some embodiments, the reference or control is tested and / or determined substantially simultaneously with the target test or determination. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by those skilled in the art, a reference or control is determined or characterized under conditions or environments comparable to those being evaluated. Those skilled in the art will understand when there is sufficient similarity to justify reliance on and / or comparison with a particular possible reference or control. In some embodiments, the reference is a negative control reference; in some embodiments, the reference is a positive control reference.
[0203] Regulatory element: As used herein, the term "regulatory element" or "regulatory sequence" refers to a non-coding region of DNA that regulates the expression of one or more specific genes in a certain way. In some embodiments, such genes are juxtaposed or "adjacent" to a given regulatory element. In some embodiments, such genes are located at a position quite far from a given regulatory element. In some embodiments, the regulatory element impairs or enhances the transcription of one or more genes. In some embodiments, the regulatory element can be located in the cis position of the regulated gene. In some embodiments, the regulatory element can be located in the trans position of the regulated gene. For example, in some embodiments, a regulatory sequence refers to a nucleic acid sequence that regulates the expression of a gene product that is operably connected to the regulatory sequence. In some such embodiments, the sequence can be an enhancer sequence and other regulatory elements that regulate the expression of a gene product.
[0204] Sample: As used herein, the term "sample" generally refers to an aliquot of a material obtained or derived from a target source. In some embodiments, the target source is a biological or environmental source. In some embodiments, the target source can be or include a cell or organism, such as a microorganism (e.g., virus), a plant or an animal (e.g., human). In some embodiments, the target source is or includes a biological tissue or fluid. In some embodiments, the biological tissue or fluid can be or include amniotic fluid, aqueous humor, ascites, bile, bone marrow, blood, milk, cerebrospinal fluid, cerumen, chyle, chime, ejaculation, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, nasal mucositis, saliva, sebum, semen, serum, smegma, sputum, synovial fluid, sweat, tears, urine, vaginal secretions, vitreous fluid, vomitus and / or combinations or components thereof. In some embodiments, biological fluid can be or include intracellular fluid, extracellular fluid, intravascular fluid (plasma), interstitial fluid, lymph and / or transcellular fluid. In some embodiments, biological fluid can be or include plant secretions. In some embodiments, biological tissue or sample can be obtained, for example, by suction, biopsy (for example, fine needle or tissue biopsy), swab (for example, oral, nasal, skin or vaginal swab), scraping, surgery, washing or lavage (for example, bronchoalveolar, duct, nasal cavity, eye, oral cavity, uterus, vagina or other washing or lavage). In some embodiments, biological sample is or includes cells obtained from individual. In some embodiments, sample is "initial sample" obtained directly from target source by any appropriate means. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing the initial sample (for example, by removing one or more components of the initial sample and / or by adding one or more reagents to the initial sample). For example, using semipermeable membrane filtration. Such a "processed sample" may include, for example, nucleic acids or proteins extracted from a sample or obtained by subjecting the initial sample to one or more techniques such as amplification or reverse transcription of nucleic acids, separation and / or purification of certain components, and the like.
[0205] Subject: As used herein, the term "subject" refers to an organism, typically a mammal (e.g., a human, including prenatal human forms in some embodiments). In some embodiments, the subject suffers from a relevant disease, disorder, or condition. In some embodiments, the subject is susceptible to a disease, disorder, or condition. In some embodiments, the subject exhibits one or more symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the subject does not exhibit any symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the subject is someone who has one or more characteristics characteristic of susceptibility to a disease, disorder, or condition or a risk of a disease, disorder, or condition. In some embodiments, the subject is a patient. In some embodiments, the subject is an individual to whom and / or to whom diagnosis and / or therapy has been administered.
[0206] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting the full or nearly full extent or degree of a characteristic or property of interest. One of ordinary skill in the art will understand that biological and chemical phenomena rarely, if ever, go to completion and / or proceed to completion or achieve or avoid an absolute result. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0207] Target site: As used herein, the term "target site" means a portion of a nucleic acid to which a binding molecule such as a microRNA, siRNA, guide RNA ("gRNA") or guide RNA:Cas complex will bind, as long as there are sufficient binding conditions. In some embodiments, the nucleic acid comprising the target site is double-stranded. In some embodiments, the nucleic acid comprising the target site is single-stranded. Typically, the target site comprises a nucleic acid sequence to which a binding molecule (e.g., a gRNA or gRNA as described herein:Cas complex) binds and / or is cut due to such binding. In some embodiments, the target site comprises a nucleic acid sequence complementary to a DNA sequence bound to a targeting sequence (also referred to herein as a spacer) of a gRNA as described herein. In some embodiments in the context of an RNA-guided nuclease (e.g., CRISPR / Cas nuclease), the target site typically comprises a nucleotide sequence complementary to a sequence (also referred to herein as a targeting sequence or spacer) contained in the gRNA of an RNA-programmable nuclease (also referred to herein as a target sequence or a spacer). In some such embodiments, the target site further comprises a protospacer adjacent motif (PAM) at the 3' end or 5' end adjacent to the gRNA-complementary sequence. For RNA-guided nuclease Cas9, in some embodiments, the target sequence can be a PAM of 16-24 base pairs plus 3-6 base pairs (e.g., NNN, where N represents any nucleotide). RNA-guided nucleases, such as exemplary PAM sequences of Cas9 are known to those skilled in the art and include, but are not limited to, NNG, NGN, NAG, NGA, NGG, NGAG, and NGCG, where N represents any nucleotide. In addition, Cas9 nucleases from different species have been described, for example, Streptococcus thermophilus recognizes a PAM comprising the sequence NGGNG, and Cas9 from Staphylococcus aureus recognizes a PAM comprising the sequence NNGRRT. In some embodiments, Cas9 from Staphylococcus aureus recognizes a PAM comprising the sequence NNNRRT. Additional PAM sequences are known in the art, including but not limited to NNAGAAW and NAAR (see, e.g., Esvelt and Wang, Molecular Systems Biology, 9:641 (2013), the entire contents of which are incorporated herein by reference). For example, a target site for an RNA-guided nuclease (such as, e.g., Cas9) can comprise the structure [Nz]-[PAM], where each N is independently any nucleotide, and z is an integer between 1 and 50.In some embodiments, z is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50. In some embodiments, z is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is 20.
[0208] Treatment: As used herein, the term "treatment" (also referred to as "treat" or "treating") refers to partially or completely alleviating, ameliorating, eliminating, reversing, alleviating, inhibiting, delaying the onset of one or more symptoms, features, and / or causes of a particular disease, disorder, and / or condition, reducing the severity of one or more symptoms, features, and / or causes of a particular disease, disorder, and / or condition, and / or reducing the incidence of one or more symptoms, features, and / or causes of a particular disease, disorder, and / or condition. In some embodiments, such treatment may be directed to subjects who do not show signs of the relevant disease, disorder, and / or condition and / or subjects who only show early signs of the disease, disorder, and / or condition. Alternatively or additionally, such treatment may be directed to subjects who show one or more established signs of the relevant disease, disorder, and / or condition. In some embodiments, treatment may be directed to subjects who have been diagnosed with the relevant disease, disorder, and / or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with an increased risk of developing a given disease, disorder, and / or condition.
[0209] Variant: As used herein, the term "variant" refers to a version of something, such as a gene sequence, that is different from another version in some way. In order to determine whether something is a variant, a reference version is usually selected, and the variant is different relative to the reference version. In some embodiments, the variant may have an activity or functional level that is the same or different (e.g., increased or decreased) from the wild-type sequence. For example, in some embodiments, if the variant is, for example, codon-optimized to resist, for example, degradation by inhibitory nucleic acids such as miRNA, it may have an improved function compared to the wild-type sequence. Such variants are referred to herein as gain-of-function variants. In some embodiments, the variant has an activity or functional reduction or elimination or an activity change that leads to negative results (e.g., increased electrical activity, which leads to chronic depolarization, which leads to cell death). Such variants are referred to herein as loss-of-function variants. In some embodiments, a gain-of-function variant is a codon-optimized sequence, and its encoded transcript or polypeptide may have improved properties (e.g., lower sensitivity to degradation, such as lower sensitivity to miRNA-mediated degradation) than its corresponding wild-type (e.g., non-codon-optimized) version. In some embodiments, a loss-of-function variant has one or more changes that cause the transcript or polypeptide to be defective (eg, reduced function, non-functional) in some manner relative to a wild-type transcript and / or polypeptide. BRIEF DESCRIPTION OF THE DRAWINGS
[0210] Figure 1 - Schematic diagram depicting an exemplary qPCR assay primer design. The schematic diagram shows different regions where primers and probes can be used in the qPCR assay. Primer and probe combinations are designed to be specific for the target virus and gene. Regions of the recombinant viral genome (for different assays) are selected that span target gene-specific sequences that are not present in that order in the human genome or AAV genome. For each assay, multiple primers and probes are designed for each region and screened for the most robust and specific combinations.
[0211] Figure 2 - Graph depicting a calibration curve of exemplary DMD AAV constructs in Siemens Storage Buffer 2 (SSB2) used for assignment, as described in Example 1.
[0212] Figure 3 - Depicts the results of precise calculations used to quantify exemplary DMD AAV constructs in saliva, feces, urine and whole blood biological samples, as described in Example 1.
[0213] Figure 4 - Depicts the stability of exemplary DMD AAV constructs in saliva, feces, urine, and whole blood biological samples over 48 hours at ambient temperature.
[0214] Figure 5 - Depicts the long-term stability of exemplary DMD AAV constructs in saliva, feces, urine, and whole blood biological samples stored at -80°C over 9 months.
[0215] Figure 6 - Characterizes the stability of exemplary DMD AAV constructs in saliva, feces, urine, and whole blood biological samples over multiple freeze / thaw cycles.
[0216] Figure 7 - Depicts the effect of MNase treatment on sample recovery of exemplary DMD AAV constructs in saliva, urine, and feces samples.
[0217] Figure 8 - Depicts the effect of MNase and DNase treatment on sample recovery of exemplary DMD AAV constructs in whole blood samples.
[0218] FIG. 9 - Depicts an exemplary quantitative assay for measuring plasma (small Fig. 9A ), PBMC (small Fig. 9B ), saliva (small Fig. 9C ), semen (small Fig.9D ), feces (small Fig.9E ) or urine (small Fig.9F ) in the linearity and accuracy of the exemplary Hem-B AAV construct.
[0219] Fig.10 - Describes an exemplary quantitative assay for measuring plasma from five unique donors (small Fig.10 A), PBMC (small Fig.10 B) Saliva (small Fig.10 C) Semen (small Fig.10 D) feces (small Fig.10 E) or urine (small Fig.10 F) Variability of exemplary Hem-B AAV constructs.
[0220] Figure 11 - Depicts the effect of MNase treatment on fluid from saliva ( Fig.11A ), semen (small Fig. 11B ), feces (small Fig. 11C ) or urine (small Fig.11D ) Effect of exemplary Hem-B AAV construct samples, double-stranded DNA or single-stranded DNA recovery on samples.
[0221] Fig.12 - Depicts the effect of MNase treatment on the recovery of exemplary Hem-B AAV construct samples from saliva, semen, feces or urine samples.
[0222] Fig.13- Depicts the stability of exemplary Hem-B AAV constructs in whole blood samples from three unique donors over 48 hours at ambient temperature.
[0223] Fig.14 -Charts plasma (small Fig.14 A), PBMC (small Fig.14 B) Saliva (small Fig.14 C) Semen (small Fig.14 D) feces (small Fig.14 E) or urine (small Fig.14 F) Stability of exemplary Hem-B AAV constructs in samples.
[0224] Fig.15 -Describe the changes in plasma (small Fig.15 A), PBMC (small Fig.15 B) Saliva (small Fig.15 C) Semen (small Fig.15 D) feces (small Fig.15 E) or urine (small Fig.15 F) Stability of exemplary Hem-B AAV constructs in samples.
[0225] Fig.16 -Depicts plasma stored at -80°C (small Fig.16 A), PBMC (small Fig.16 B) Saliva (small Fig.16 C) Semen (small Fig.16 D) feces (small Fig.16 E) or urine (small Fig.16 F) Long-term stability of exemplary Hem-B AAV constructs in samples.
[0226] FIG. 17 - depicts a series of quantitative PCR amplification plots for quantification of an exemplary DMD AAV construct. Targeting region 1 of an exemplary DMD AAV construct is the primer and probe combination DMD-FWD-B (SEQ ID NO: 3), DMD-REV-A (SEQ ID NO: 9) and DMD-probe-A (SEQ ID NO: 17) (small Fig.17A ). An exemplary DMD AAV construct targeting region 2 is the primer and probe combination DMD-FWD-E (SEQ ID NO: 63), DMD-REV-E (SEQ ID NO: 67), and DMD-probe-F (SEQ ID NO: 73) (small Fig. 17B ).
[0227] FIG. 18 - depicts a series of quantitative PCR amplification plots for quantification of an exemplary DMD AAV construct and a quantitative internal control (IC). The exemplary DMD AAV construct targeting region 3 is the primer and probe combination DMD-FWD-F (SEQ ID NO: 69), DMD-REV-G (SEQ ID NO: 71) and DMD-probe-G (SEQ ID NO: 77) (small Fig.18A ). Targeting the internal control DNA are primers and probes containing Cy5 fluorescence ( Fig.18B ).
[0228] FIG. 19 - A series of results depicting quantitative PCR amplification characteristics (such as maximum fluorescence, slope, and earliest Ct) of primer and probe combinations targeting DMD multiplexed with primer and probe combinations targeting internal control DNA pools (small Fig.19A ). Group 1 represents the combination of DMD-FWD-A (SEQ ID NO: 1), DMD-REV-B (SEQ ID NO: 11) and DMD-probe-A (SEQ ID NO: 17). Group 2 represents the combination of DMD-FWD-A (SEQ ID NO: 1), DMD-REV-B (SEQ ID NO: 11) and DMD-probe-B (SEQ ID NO: 21). Group 3 represents the combination of DMD-FWD-B (SEQ ID NO: 3), DMD-REV-A (SEQ ID NO: 9) and DMD-probe-A (SEQ ID NO: 17). Group 4 represents the combination of DMD-FWD-C (SEQ ID NO: 5), DMD-REV-D (SEQ ID NO: 15) and DMD-probe-D (SEQ ID NO: 29). Group 5 represents a combination of DMD-FWD-D (SEQ ID NO: 7), DMD-REV-C (SEQ ID NO: 13) and DMD-probe-C (SEQ ID NO: 25). In addition, various concentrations of DMD-specific oligonucleotides (small Fig.19A ) and IC-specific oligonucleotides (small Fig.19B )'s primers and probes.
[0229] FIG20 - depicts a series of quantitative PCR amplification plots for quantification of an exemplary Hem-B AAV construct. Targeting region 1 of an exemplary DMDAAV construct is the primer and probe combination HemB-FWD-A (SEQ ID NO: 33), HemB-REV-A (SEQ ID NO: 39), and HemB-probe-A (SEQ ID NO: 47) ( Fig. 20A). An exemplary Hem-B AAV construct targeting region 2 is the primer and probe combination HemB-FWD-B (SEQ ID NO: 35), HemB-REV-D (SEQ ID NO: 45), and HemB-probe-C (SEQ ID NO: 55) (small Fig. 20B ). An exemplary Hem-B AAV construct targeting region 3 is the primer and probe combination HemB-FWD-D (SEQ ID NO: 81), HemB-REV-F (SEQ ID NO: 87), and HemB-probe-E (SEQ ID NO: 89) ( Fig. 20C ).
[0230] Fig.21- A series of results depicting quantitative PCR amplification characteristics (such as maximum fluorescence, slope, and earliest Ct) of primer and probe combinations targeting exemplary Hem-B AAV constructs. Group 1 represents the combination of HemB-FWD-B (SEQ ID NO: 35), HemB-REV-C (SEQ ID NO: 43), and HemB-probe-B (SEQ ID NO: 51), with a final concentration of 150 nM for each oligonucleotide. Group 2 represents the combination of HemB-FWD-B (SEQ ID NO: 35), HemB-REV-C (SEQ ID NO: (43) and HemB-probe-B (SEQ ID NO: (51), and the final concentration of each oligonucleotide is 200 nM. Group 3 represents the combination of HemB-FWD-C (SEQ ID NO: 37), HemB-REV-B (SEQ ID NO: 41) and HemB-probe-D (SEQ ID NO: 59), and the final concentration of each oligonucleotide is 250 nM. Group 4 represents the combination of HemB-FWD-C (SEQ ID NO: 37), HemB-REV-B (SEQ ID NO: 41) and HemB-probe-D (SEQ ID NO: 59), and the final concentration of each oligonucleotide is 300 nM. Group 5 represents HemB-FWD-B (SEQ ID NO: 35), HemB-REV-D (SEQ ID NO: 45) and HemB-probe-C (SEQ ID NO: Group 6 represents the combination of HemB-FWD-B (SEQ ID NO:35), HemB-REV-D (SEQ ID NO:45) and HemB-probe-C (SEQ ID NO:55), and the final concentration of each oligonucleotide is 150 nM. Group 7 represents the combination of HemB-FWD-E (SEQ ID NO:83), HemB-REV-F (SEQ ID NO:85) and HemB-probe-E (SEQ ID NO:89), and the final concentration of each oligonucleotide is 200 nM. Group 8 represents the combination of HemB-FWD-D (SEQ ID NO:81), HemB-REV-F (SEQ ID NO:87) and HemB-probe-E (SEQ ID NO:89), and the final concentration of each oligonucleotide is 200 nM. Group 9 represents HemB-FWD-D (SEQ ID NO:35), HemB-REV-D (SEQ ID NO:45) and HemB-probe-C (SEQ ID NO:55), and the final concentration of each oligonucleotide is 150 nM. Group 10 represents the combination of HemB-FWD-E (SEQ ID NO:83), HemB-REV-F (SEQ ID NO:85) and HemB-probe-E (SEQ ID NO:89), and the final concentration of each oligonucleotide is 200 nM. NO:81), HemB-REV-F (SEQ ID NO:87) and HemB-probe-E (SEQ ID NO:89), with the final concentration of each oligonucleotide being 300 nM.Group 10 represents a combination of HemB-FWD-A (SEQ ID NO: 33), HemB-REV-A (SEQ ID NO: 39) and HemB-probe-A (SEQ ID NO: 47), with a final concentration of 150 nM for each oligonucleotide. Groups 1-6 target region 2 of an exemplary Hem-B AAV construct, groups 7-9 target region 3 of an exemplary Hem-B AAV construct, and group 10 targets region 1 of an exemplary Hem-B AAV construct.
[0231] FIG. 22 - depicts a method for using primer probe combination set 10 (small Fig.22A ), Group 6 (small Fig. 22B ) and Group 9 (small Fig. 22C ) A series of quantitative PCR amplification plots quantifying exemplary Hem-B AAV constructs.
[0232] Fig.23 - An exemplary collection of quantitative PCR amplification results depicting multiplexed exemplary Hem-B AAV construct amplification and exemplary internal control amplification in the following six tissue types: feces, plasma, PMBC, saliva, semen, and urine. DETAILED DESCRIPTION
[0233] Gene therapy
[0234] Gene therapy refers to techniques involving the introduction of genes or modification of gene expression to treat, improve and / or prevent disease. There are several approaches to gene therapy, including, but not limited to: replacing disease-causing mutant genes with healthy gene copies; inactivating or "knocking out" mutant genes that function improperly; and / or introducing genes into the body to help fight disease. Gene therapy is a promising treatment option for many diseases, including genetic disorders, certain types of cancer, and certain viral infections. Typically, gene therapy is tested for diseases with known genetic associations and / or diseases that are considered to lack current standards of care.
[0235] Clinical trials involving gene therapy technologies are subject to regulations that may require certain monitoring guidelines to be met. One such regulation involving viral delivery methods requires accurate and often continuous measurement of viral dose and viral "shedding" (viral particles released from a test subject by any mechanism). The present disclosure provides compositions and methods that facilitate basic monitoring of viral shedding, providing physicians and scientists with robust and reliable measurements.
[0236] Example conditions
[0237] Duchenne muscular dystrophy
[0238] Duchenne muscular dystrophy (DMD) is an X-linked recessive disease that affects approximately 1 in 5000 live male births (Mendell et al., 2012; and Moat et al., 2013; both of which are incorporated herein by reference for any purpose). It was first described in detail in the 1860s by French neurologist Guillaume-Benjamin-Amand Duchenne (Duchenne 1861, which is incorporated herein by reference for any purpose). Patients with Duchenne muscular dystrophy usually show motor symptoms within the first 3 years of life. Most commonly, they may have a "waddling" gait caused by hip girdle weakness, and need to use their hands when they stand up from the floor (Gall's maneuver).
[0239] The disease is due to the absence of dystrophin in the skeletal muscle membrane, and muscles lacking dystrophin are more susceptible to mechanical damage. The absence of dystrophin can be demonstrated by the absence of dystrophin immunostaining in muscle biopsy samples. However, genetic testing has become more accessible in recent years and has become a standard method for diagnostic confirmation. Typically, genetic testing starts with screening for duplication or deletion by multiplex ligation-dependent probe amplification (MLPA) or by microarray analysis. If the duplication / deletion test is negative, all 79 exons are sequenced to detect missense, nonsense, splice sites, and small insertion and deletion mutations (Birnkrant et al., Part 3, 2018; Incorporated herein by reference for any purpose). According to the genetic test results, various gene therapy approaches may be obtained.
[0240] The DMD gene is considered to be one of the largest genes in the human genome, and many damaging mutations have been reported. De novo mutations appear to be common, with estimates ranging from 12% to 33% of patients having DMD (Shieh, 2018; it is incorporated herein by reference for any purpose). Estimates of the prevalence of different mutation types vary, but reports indicate that in DMD patients, 69% have large deletions, 11% have large duplications, 10% have nonsense mutations, 7% have missense or small insertions and deletions, and another 3% have introns or other mutations (Shieh, 2018; it is incorporated herein by reference for any purpose). The large size of dystrophin means that full gene replacement therapy for DMD is only feasible for large viruses, such as adenoviral vectors. Alternatively, a miniaturized but effective form of dystrophin (commonly referred to as "mini-dystrophin" or "micro-dystrophin") can be used instead of introducing the entire large DMD gene. These small genes are often small enough to be packaged in adeno-associated viruses (AAV). Over the past 16 years, experience with preclinical and clinical studies with AAV has grown to provide a better understanding of the safety profile of these viruses. This experience and knowledge base has made AAV vector delivery of gene therapies a key clinical candidate, including treatment of muscular dystrophy by delivering micro / mini-dystrophin genes. Although AAV-based gene therapies may be a breakthrough, there remains a critical need for accurate and reproducible materials and methods to monitor AAV shedding in patients treated with gene therapy for DMD.
[0241] Hemophilia B
[0242] Hemophilia B, also known as factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by a lack or defect in the blood clotting protein factor IX. Although it is passed down from parents to children, about 1 / 3 of cases are caused by de novo mutations. According to the Centers for Disease Control and Prevention, hemophilia occurs in approximately 1 in 5,000 live infants. About 20,000 people in the United States have hemophilia. All races and ethnicities are affected. The incidence of hemophilia B is four times less than that of hemophilia A. Patients with hemophilia B have longer bleeding than others. Bleeding may occur internally, in joints and muscles, or externally, from minor cuts, dental surgery or trauma. The frequency of bleeding in a person and the severity of bleeding depend on how much FIX is in the plasma, and hemophilia B is tested using an assay that assesses clotting time. In addition, genetic testing is used to determine the underlying molecular mechanism of an individual's hemophilia B, because more than 1,100 unique mutations are known to cause hemophilia B.
[0243] The mainstay of treatment for hemophilia B is concentrated FIX products, called clotting factors or simply factors. Recombinant factor products developed in the laboratory using DNA technology preclude the use of plasma pools derived from human donors. Although plasma-derived FIX products are still available, approximately 75% of the hemophilia community uses recombinant FIX products. These factor therapies are infused intravenously through a vein in the arm or a port in the chest, and patients often require conventional expensive, time-consuming and cumbersome treatments. Gene therapy has proven to be suitable and potentially highly effective for treating hemophilia B. However, while AAV-based gene therapy may be a breakthrough, there is still a pressing need for accurate and reproducible materials and methods to monitor AAV shedding in patients using gene therapy for hemophilia B.
[0244] Viral vectors for therapeutic use
[0245] The present disclosure provides, among other things, compositions and methods for measuring polynucleotides.Polynucleotide constructs according to the present disclosure include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes) and viral constructs (e.g., lentiviral, retroviral, adenoviral and adeno-associated viral constructs), which incorporate a target polynucleotide sequence or a characteristic portion thereof.
[0246] Those skilled in the art will be able to select suitable constructs for measurement. In some embodiments, the construct is a viral construct. In some embodiments, the viral construct is a lentivirus, a retrovirus, an adenovirus or an adeno-associated virus construct. In some embodiments, the construct is an adeno-associated virus (AAV) construct (see, e.g., Asokan et al., Mol. Ther. 20:699-7080, 2012, which is incorporated herein by reference in its entirety). In some embodiments, the viral construct is an adenovirus construct. In some embodiments, the viral construct may also be based on or derived from an alpha virus. Alphaviruses include Sindbis (and VEEV) virus, Aura virus, Babanki virus, Bama Forest virus, Bibaru virus, Kabaso virus, Chikungunya virus, Eastern equine encephalitis virus, Everglades virus, Fort Morgan virus, Geta virus, Highlands J virus, Zilagachi virus, Mayaro virus, Me Tri virus, Middelburg virus, Mosso das Pedras virus, Mukambo virus, Ndumau virus, O'nyong-nyong virus, Pixuna virus, Rio Negro virus, Ross River virus, Salmon pancreatic disease virus, Semliki Forest virus, Southern elephant seal virus, Tunat virus, Trocara virus, Una virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, and Vataroa virus. Typically, the genome of such viruses encodes nonstructural proteins (e.g., replicons) and structural proteins (e.g., capsid and envelope) that can be translated in the cytoplasm of the host cell. Ross River virus, Sindbis virus, Semliki Forest virus (SFV) and Venezuelan equine encephalitis virus (VEEV) have all been used to develop viral constructs for coding sequence delivery. Pseudotyped viruses can be formed by combining alphavirus envelope glycoproteins and retroviral capsids. Examples of alphavirus constructs can be found in U.S. Publication Nos. 20150050243, 20090305344 and 20060177819; constructs and methods for their manufacture are incorporated herein by reference in their entirety for each publication.
[0247] Constructs suitable for measurement may have different sizes. In some embodiments, the construct is a plasmid and can include up to about 1 kb, up to about 2 kb, up to about 3 kb, up to about 4 kb, up to about 5 kb, up to about 6 kb, up to about 7 kb, up to about 8 kb, up to about 9 kb, up to about 10 kb, up to about 11 kb, up to about 12 kb, up to about 13 kb, up to about 14 kb, or up to about 15 kb in total length. In some embodiments, the construct is a plasmid and can have a total length in the range of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 1 kb to about 11 kb, about 1 kb to about 12 kb, about 1 kb to about 13 kb, about 1 kb to about 14 kb, or about 1 kb to about 15 kb.
[0248] In some embodiments, the construct is a viral construct and can have a total nucleotide length of up to 10 kb. In some embodiments, the viral construct can have a total nucleotide length of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 2 kb to about 9 kb, about 2 kb to about 10 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, about 3 kb to about 6 kb, about 3 kb to about 7 kb, about 3 kb to about 8 kb, about 3 kb to about The total number of nucleotides in a range of about 9 kb, about 3 kb to about 10 kb, about 4 kb to about 5 kb, about 4 kb to about 6 kb, about 4 kb to about 7 kb, about 4 kb to about 8 kb, about 4 kb to about 9 kb, about 4 kb to about 10 kb, about 5 kb to about 6 kb, about 5 kb to about 7 kb, about 5 kb to about 8 kb, about 5 kb to about 9 kb, about 5 kb to about 10 kb, about 6 kb to about 7 kb, about 6 kb to about 8 kb, about 6 kb to about 9 kb, about 6 kb to about 10 kb, about 7 kb to about 8 kb, about 7 kb to about 9 kb, about 7 kb to about 10 kb, about 8 kb to about 9 kb, about 8 kb to about 10 kb, or about 9 kb to about 10 kb.
[0249] In some embodiments, the construct is a lentiviral construct and can have a total nucleotide length of up to 8 kb. In some examples, the lentiviral construct can have a total nucleotide length of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 3 kb. The total number of nucleotides from about 4 kb to about 5 kb, from about 3 kb to about 6 kb, from about 3 kb to about 7 kb, from about 3 kb to about 8 kb, from about 4 kb to about 5 kb, from about 4 kb to about 6 kb, from about 4 kb to about 7 kb, from about 4 kb to about 8 kb, from about 5 kb to about 6 kb, from about 5 kb to about 7 kb, from about 5 kb to about 8 kb, from about 6 kb to about 8 kb, from about 6 kb to about 7 kb, or from about 7 kb to about 8 kb.
[0250] In some embodiments, the construct is an adenoviral construct and can have a total nucleotide size of up to 8 kb. In some embodiments, the adenoviral construct can have a total nucleotide size of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 3 ... The total number of nucleotides in the range of about 4kb, about 3kb to about 5kb, about 3kb to about 6kb, about 3kb to about 7kb, about 3kb to about 8kb, about 4kb to about 5kb, about 4kb to about 6kb, about 4kb to about 7kb, about 4kb to about 8kb, about 5kb to about 6kb, about 5kb to about 7kb, about 5kb to about 8kb, about 6kb to about 7kb, about 6kb to about 8kb, or about 7kb to about 8kb.
[0251] AAV for therapeutic use
[0252] Previous studies have identified adeno-associated virus (AAV) as a suitable vector for delivering therapeutic oligonucleotides to subjects in need thereof.
[0253] Gene therapy is rapidly evolving for the treatment of genetic disorders, and for many patients, the success of these therapies is their only hope for a cure (Angeula & High 2019; and Carlton 2018). During gene therapy, a healthy copy of the disease-causing gene is delivered to the patient via a viral vector (Angeula & High, 2019; and Carlton, 2018). Many regulatory agencies (EMA, FDA, etc.) require monitoring of shed viruses as part of gene therapy clinical trials (FDA, 2015; ICH, 2009; GTWP, BWP and SWP, 2008; and Bubela et al., 2019). Detection of viruses in body fluids may be crucial for understanding environmental consequences or potential long-term effects that may lead to an increase in neutralizing antibodies (NAbs) against adeno-associated viruses in society (Bubela et al., 2019; and Rodrigues et al., 2018).
[0254] One of the most common gene therapy vectors is adeno-associated virus (AAV). AAV is used because of its apparent lack of pathogenesis and replication capacity (Angeula & High 2019; and Carlton 2018). Patients undergoing recombinant AAV (rAAV) gene therapy treatment are injected with high titers of rAAV. Patients undergoing this treatment clear excess virus through a process called shedding. Shedding refers to the excretion or release of vector-based gene therapy products from a patient's excreta (feces), secretions (urine, saliva, and semen), or blood products (whole blood, plasma, or PBMC) (FDA, 2015; ICH, 2009; GTWP, BWP, and SWP, 2008; and Bubela et al., 2019). Even though AAV is not pathogenic, shedding poses a possible risk to people who encounter patients undergoing gene therapy treatment. The risk of exposure to the virus may lead to an increase in neutralizing antibodies against AAV and rAAV-based therapies in society (Bubela et al., 2019; and Rodrigues et al., 2018). Monitoring virus concentrations in shedding patient samples is necessary to understand possible modes of vector-borne transmission and is a requirement of multiple regulatory agencies.
[0255] There are two key requirements for developing a shedding assay: the assay must be developed for a variety of sample types and must be quantitative (FDA, 2015). This article describes a novel composition comprising specific primers for quantifying viral DNA in patient samples ( Figure 1 These compositions are suitable for quantitative polymerase chain reaction (qPCR) for quantifying viral DNA in a sample ( Figure 1). One challenge is the ability to consistently purify viral DNA from a variety of complex matrices. Therefore, materials and methods that can produce reproducible, efficient, and scalable viral DNA extraction and quantification from shed samples are needed.
[0256] New compositions and protocols for monitoring viral shed DNA from many different bodily fluids, including semen, saliva, urine, whole blood, PBMCs, plasma, and feces, are described herein. The data presented represent optimized quantification protocols from various shedding compartment cohorts to establish consistent and reproducible shedding assays.
[0257] Viral shedding
[0258] Existing DNA quantification and / or sequencing materials and methods for accurately detecting, identifying and quantifying foreign and / or therapeutic oligonucleotides are often found to be inadequate. Specifically, current materials and methods for quantifying gene therapy constructs shed from clinical samples and / or patients often fail to accurately and reproducibly quantify shed constructs and / or genomic titers to levels described by appropriate regulatory and / or advisory agencies (e.g., GTWP, BWP, SWP and / or FDA).
[0259] In some embodiments, the materials and methods described herein can detect and quantitatively find gene therapy constructs that are not bound and / or free oligonucleotides. In some embodiments, the materials and methods described herein can detect and quantitatively find gene therapy constructs associated with viral particles. As described herein, there are many suitable gene therapy vectors (e.g., viral particles) that can accommodate gene therapy oligonucleotides, which are easily quantified using the materials and methods described herein. In certain embodiments, the gene therapy constructs detected and quantified are oligonucleotides associated with recombinant adeno-associated virus (rAAV) particles.
[0260] Previous assays have not demonstrated adequate performance to be widely accepted in clinical laboratories and have not been submitted for regulatory approval. Due to these performance limitations, most have been used as research assays or local homebrew laboratory developed tests. Previous assay designs have not addressed these limitations.
[0261] In contrast, the present disclosure leads to unique high-performance assay design prototypes. The best performing designs meet the IVD commercialization standard of successfully amplifying >95% with known global sequence variants. This performance standard has previously been shown to demonstrate sufficient sensitivity across genetic variants to implement routine clinical use on samples in international studies.
[0262] Measuring virus-associated oligonucleotide construct titers from biological sources
[0263] In some embodiments, the compositions and methods described herein can be used to detect and quantify oligonucleotide constructs delivered by rAAV particles. In some embodiments, detection and quantification are performed on samples obtained from patients and are measurements of viral shedding. In some embodiments, virus-associated oligonucleotide constructs shed from patients can be directed to specific gene therapy constructs, such as, but not limited to, constructs for the treatment of Duchenne muscular dystrophy and / or hemophilia B.
[0264] Amplification oligonucleotide sequences and primer sets
[0265] In some embodiments, the compositions described herein comprise forward and reverse oligonucleotides suitable and specific for the amplification and subsequent quantification of known gene therapy constructs. In some embodiments, the compositions comprising forward and reverse amplification oligonucleotides may additionally comprise sequence-specific probes suitable for real-time quantification of amplicon products. In some embodiments, the sequence-specific probes may be for use with TaqMan TM The quantitative polymerase chain reaction (qPCR) protocol was used to design probes for amplicon quantification.
[0266] In some embodiments, quantitative probes and primers can be designed to hybridize with sequences specific to non-naturally occurring construct-specific connections. In some embodiments, the connection can span constructs to regulatory elements, (e.g., span rAAV inverted terminal repeats to promoters and / or 3'UTR regions). In some embodiments, the connection can span regulation to regulatory elements, (e.g., span promoters to enhancer connections, and / or span 3'UTR to poly A signal sequences). In some embodiments, the connection can span regulation to payload elements (e.g., span promoters and / or 3'UTR regions to gene therapy-specific payload sequences, i.e., dystrophin, micro-dystrophin, and / or factor IX). In some embodiments, the connection can span constructs to payload elements (e.g., span rAAV inverted terminal repeats to gene therapy-specific payload sequences).
[0267] In some embodiments, primers and / or probes can be screened to determine the total pool of primers and / or probes suitable for multiplexing. In some embodiments, one or more primers and / or one or more probes can be used in multiple determinations. In certain embodiments, primers and / or probes are screened for crosstalk and / or undesirable oligonucleotide interactions. In some embodiments, primers and / or probes are tested to assess their specificity when additionally exposed to background genomic DNA. In some embodiments, candidate primers and / or probes are further optimized to include addition, truncation and / or nucleotide modification to increase assay performance. In certain embodiments, primers and / or probes are tested with a variety of different concentrations (e.g., 100nM, 200M, 300nM, 400nM and / or 500nM) to increase assay performance. In some embodiments, specific primers and / or probe combinations can be used to increase assay performance. In some embodiments, any or all of the factors described herein can be used to determine appropriate primers and / or primer and probe groups to accurately amplify and / or quantify AAV constructs.
[0268] In some embodiments, the active fragment of an oligonucleotide described herein is at most the length of a particular primer and / or probe minus one nucleotide. In some embodiments, the active fragment is at most 29 nucleotides, at most 28 nucleotides, at most 27 nucleotides, at most 26 nucleotides, at most 25 nucleotides, at most 24 nucleotides, at most 23 nucleotides, at most 22 nucleotides, at most 21 nucleotides, at most 20 nucleotides, at most 19 nucleotides, at most 18 nucleotides, at most 17 nucleotides, at most 16 nucleotides, at most 15 nucleotides, at most 14 nucleotides, at most 13 nucleotides, at most 12 nucleotides, at most 11 nucleotides, or at most 10 nucleotides.
[0269] In some embodiments, primer combinations and / or primer and probe combinations can be multiplexed with additional primers and / or primer and probe sets. In some embodiments, the sensitivity of primer combinations and / or primer and probe combinations can be altered by multiplexing (e.g., if the CT of a single assay appears much earlier than in a multiplex assay, the multiplex assay may have an inhibitory effect and this may change the overall sensitivity). In some embodiments, the specificity of primer combinations and / or primer and probe combinations can be altered by multiplexing (e.g., if in a multiplex assay in which primers and / or primer and probe combinations are given multiple target DNA populations as a template, a particular primer combination and / or primer and probe combination may not produce a signal in the absence of its target DNA population, and if a signal is present, the specificity may be lower than in the absence of the additional DNA population).
[0270] Oligonucleotide sequences for DMDAAV-specific quantification
[0271] The following primer sequences are each provided in 5' to 3' order; those skilled in the art will recognize that in certain embodiments, the polynucleotide can be an RNA molecule or a DNA molecule. In certain embodiments, the initial screening includes the evaluation of 37 primer combinations and 9 different probes, ultimately producing 40 different primer-probe combinations.
[0272] SEQD:DMD-FW-A
[0273]
[0274] SEQ ID NO: 2-DMD-FWD-AU
[0275]
[0276] SEQ ID NO: 3—DMD-FWD-B
[0277]
[0278] SEQ ID NO: 4-DMD-FWD-BU
[0279]
[0280] SEQ ID NO: 5-DMD-FWD-C
[0281]
[0282] SEQ ID NO: 6-DMD-FWD-CU
[0283]
[0284] SEQ D NO: 7-DMD-FWD-D
[0285]
[0286] SEQ ID NO: 8-DMD-FWD-DU
[0287]
[0288] SEQ ID NO: 9-DMD-REV-A
[0289]
[0290] SEQ ID NO: 10-DMD-REV-AU
[0291]
[0292] SEQ ID NO: 11 - DMD - REV - B
[0293]
[0294] SEQ ID NO: 12 - DMD - REV - B.U
[0295]
[0296] SEQ ID NO: 13 - DMD - REV - C
[0297]
[0298] SEQ ID NO: 14 - DMD - REV - C.U
[0299]
[0300] SEQ ID NO: 15 - DMD - REV - D
[0301]
[0302] SEQ ID NO: 16 - DMD - REV - D.U
[0303]
[0304] SEQ ID NO: 17 - DMD - Probe - A
[0305]
[0306] SEQ ID NO: 18 - DMD - Probe - A.U
[0307]
[0308] SEQ ID NO: 19 - DMD - Probe - A.0
[0309]
[0310] SEQ ID NO: 20 - DMD - Probe - A.0.U
[0311]
[0312] SEQ ID NO: 21 - DMD - Probe - B
[0313]
[0314] SEQ ID NO: 22 - DMD - Probe - B.U
[0315]
[0316] SEQ ID NO:23-DMD-probe-B.0
[0317]
[0318] SEQ ID NO:24-DMD-probe-B.0.U
[0319]
[0320] SEQ ID NO:25-DMD-probe-C
[0321]
[0322] SEQ ID NO:26-DMD-probe-CU
[0323]
[0324] SEQ ID NO:27-DMD-probe-C.0
[0325]
[0326] SEQ ID NO:28-DMD-probe-C.0.U
[0327]
[0328] SEQ ID NO:29-DMD-probe-D
[0329]
[0330] SEQ ID NO:30-DMD-probe-DU
[0331]
[0332] SEQ ID NO:31-DMD-probe-D.0
[0333]
[0334] SEQ ID NO:32-DMD-probe-D.0.U
[0335]
[0336] SEQ ID NO: 63-DMD-FWD-E
[0337]
[0338] SEQ ID NO: 64 - DMD - FWD - E.U
[0339]
[0340] SEQ ID NO: 65 - DMD - FWD - F
[0341]
[0342] SEQ ID NO: 66 - DMD - FWD - F.U
[0343]
[0344] SEQ ID NO: 67 - DMD - REV - E
[0345]
[0346] SEQ ID NO: 68 - DMD - REV - E.U
[0347]
[0348] SEQ ID NO: 69 - DMD - REV - F
[0349]
[0350] SEQ ID NO: 70 - DMD - REV - F.U
[0351]
[0352] SEQ ID NO: 71 - DMD - REV - G
[0353]
[0354] SEQ ID NO: 72 - DMD - REV - G.U
[0355]
[0356] SEQ ID NO: 73 - DMD - Probe - F
[0357]
[0358] SEQ ID NO: 74 - DMD - Probe - F.U
[0359]
[0360] SEQ ID NO:75-DMD-probe-F.0
[0361]
[0362] SEQ ID NO:76-DMD-probe-F.0.U
[0363]
[0364] SEQ ID NO:77-DMD-probe-G
[0365]
[0366] SEQ ID NO:78-DMD-probe-GU
[0367]
[0368] SEQ ID NO:79-DMD-probe-G.0
[0369]
[0370] SEQ ID NO:80-DMD-probe-G.0.U
[0371]
[0372] Oligonucleotide panel for DMDAAV-specific quantification
[0373] In some embodiments, primer combinations can be used for accurate and specific DMD AAV quantification.
[0374] In some embodiments, the combination of primers may include one or more forward primers. In some embodiments, the combination of primers may include one or more reverse primers. In some embodiments, one or more forward primers may include SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66 or a combination thereof, or consist of it. In some embodiments, one or more reverse primers may include SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72 or a combination thereof, or consist of it.
[0375] In some embodiments, the composition comprises a combination of primers and one or more probes. In some embodiments, the one or more probes may comprise, or consist of, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, or a combination thereof.
[0376] In some embodiments, the primer combination comprises DMD-FWD-A (SEQ ID NO: 1) and DMD-REV-B (SEQ ID NO: 11). In some embodiments, the primer combination comprising DMD-FWD-A (SEQ ID NO: 1) and DMD-REV-B (SEQ ID NO: 11) is coupled to the probe sequence DMD-probe-A (SEQ ID NO: 17). In some embodiments, the primer combination comprising DMD-FWD-A (SEQ ID NO: 1) and DMD-REV-B (SEQ ID NO: 11) is coupled to the probe sequence DMD-probe-B (SEQ ID NO: 21).
[0377] In some embodiments, the primer combination comprises DMD-FWD-B (SEQ ID NO: 3) and DMD-REV-A (SEQ ID NO: 9). In some embodiments, the primer combination comprising DMD-FWD-B (SEQ ID NO: 3) and DMD-REV-A (SEQ ID NO: 9) is coupled to the probe sequence DMD-probe-A (SEQ ID NO: 17).
[0378] In some embodiments, the primer combination comprises DMD-FWD-E (SEQ ID NO: 63) and DMD-REV-E (SEQ ID NO: 67). In some embodiments, the primer combination comprising DMD-FWD-E (SEQ ID NO: 63) and DMD-REV-E (SEQ ID NO: 67) is coupled to the probe sequence DMD-probe-F (SEQ ID NO: 73).
[0379] In some embodiments, the primer combination comprises DMD-FWD-F (SEQ ID NO: 69) and DMD-REV-G (SEQ ID NO: 71). In some embodiments, the primer combination comprising DMD-FWD-F (SEQ ID NO: 69) and DMD-REV-G (SEQ ID NO: 71) is coupled to the probe sequence DMD-probe-G (SEQ ID NO: 77).
[0380] In some embodiments, the primer combination comprises DMD-FWD-B (SEQ ID NO: 3) and DMD-REV-A (SEQ ID NO: 9). In some embodiments, the primer combination comprising DMD-DMD-FWD-B (SEQ ID NO: 3) and DMD-REV-A (SEQ ID NO: 9) is coupled to the probe sequence DMD-probe-A (SEQ ID NO: 17).
[0381] In some embodiments, the primer combination comprises DMD-FWD-C (SEQ ID NO: 5) and DMD-REV-D (SEQ ID NO: 15). In some embodiments, the primer combination comprising DMD-FWD-C (SEQ ID NO: 5) and DMD-REV-D (SEQ ID NO: 15) is coupled to the probe sequence DMD-probe-D (SEQ ID NO: 29).
[0382] In some embodiments, the primer combination comprises DMD-FWD-D (SEQ ID NO: 7) and DMD-REV-C (SEQ ID NO: 13). In some embodiments, the primer combination comprising DMD-FWD-D (SEQ ID NO: 7) and DMD-REV-C (SEQ ID NO: 13) is coupled to the probe sequence DMD-probe-C (SEQ ID NO: 25).
[0383] Oligonucleotide sequences for HEM-B AAV-specific quantification
[0384] The following primer sequences are each provided in 5' to 3' order; those skilled in the art will recognize that in certain embodiments, the polynucleotide can be an RNA molecule or a DNA molecule. In certain embodiments, the initial screening includes the evaluation of 72 primer combinations and 5 different probes, ultimately producing 47 different primer-probe combinations.
[0385] SEQ ID NO: 33-HemB-FWD-A
[0386]
[0387] SEQ ID NO: 34-HemB-FWD-AU
[0388]
[0389] SEQ ID NO: 35-HemB-FWD-B
[0390]
[0391] SEQ ID NO: 36-HemB-FWD-BU
[0392]
[0393] SEQ DNO: 37-HemB-FWD-C
[0394]
[0395] SEQ ID NO: 38 - HemB - FWD - C.U
[0396]
[0397] SEQ ID NO: 39 - HemB - REV - A
[0398]
[0399] SEQ ID NO: 40 - HemB - REV - A.U
[0400]
[0401] SEQ ID NO: 41 - HemB - REV - B
[0402]
[0403] SEQ ID NO: 42 - HemB - REV - B.U
[0404]
[0405] SEQ ID NO: 43 - HemB - REV - C
[0406]
[0407] SEQ ID NO: 44 - HemB - REV - C.U
[0408]
[0409] SEQ ID NO: 45 - HemB - REV - D
[0410]
[0411] SEQ ID NO: 46 - HemB - REV - D.U
[0412]
[0413] SEQ ID NO: 47 - HemB - Probe - A
[0414]
[0415] SEQ ID NO: 48 - HemB - Probe - A.U
[0416]
[0417] SEQ ID NO:49-HemB-probe-A.0
[0418]
[0419] SEQ ID NO:50-HemB-probe-A.0.U
[0420]
[0421] SEQ ID NO:51-HemB-probe-B
[0422]
[0423] SEQ ID NO:52-HemB-probe-BU
[0424]
[0425] SEQ ID NO:53-HemB-probe-B.0
[0426]
[0427] SEQ ID NO:54-HemB-probe-B.0.U
[0428]
[0429] SEQ ID NO:55-HemB-probe-C
[0430]
[0431] SEQ ID NO:56-HemB-probe-CU
[0432]
[0433] SEQ ID NO:57-HemB-probe-C.0
[0434]
[0435] SEQ ID NO:58-HemB-probe-C.0.U
[0436]
[0437] SEQ ID NO:59-HemB-Probe-D
[0438]
[0439] SEQ ID NO:60 - HemB - Probe - D.U
[0440]
[0441] SEQ ID NO:61 - HemB - Probe - D.0
[0442]
[0443] SEQ ID NO:62 - HemB - Probe - D.0.U
[0444]
[0445] SEQ ID NO:81 - HemB - FWD - D
[0446]
[0447] SEQ ID NO:82 - HemB - FWD - D.U
[0448]
[0449] SEQ ID NO:83 - HemB - FWD - E
[0450]
[0451] SEQ ID NO:84 - HemB - FWD - E.U
[0452]
[0453] SEQ ID NO:85 - HemB - REV - E
[0454]
[0455] SEQ ID NO:86 - HemB - REV - E.U
[0456]
[0457] SEQ ID NO:87 - HemB - REV - F
[0458]
[0459] SEQ ID NO:88 - HemB - REV - F.U
[0460]
[0461] SEQ ID NO:89-HemB-probe-E
[0462]
[0463] SEQ ID NO:90-HemB-probe-EU
[0464]
[0465] SEQ ID NO:91-HemB-probe-E.0
[0466]
[0467] SEQ ID NO:92-HemB-probe-E.0.U
[0468]
[0469] Oligonucleotide combination for specific quantification of HEM-BAAV
[0470] In some embodiments, primer combinations can be used for accurate and specific Hem-B AAV quantification.
[0471] In some embodiments, the combination of primers may include one or more forward primers. In some embodiments, the combination of primers may include one or more reverse primers. In some embodiments, one or more forward primers may include SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, or a combination thereof, or consist of it. In some embodiments, one or more reverse primers may include SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, or a combination thereof, or consist of it.
[0472] In some embodiments, the composition comprises a combination of primers and one or more probes. In some embodiments, the one or more probes may comprise, or consist of, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:91, SEQ ID NO:92, or a combination thereof.
[0473] In some embodiments, the primer combination comprises HemB-FWD-B (SEQ ID NO: 35) and HemB-REV-D (SEQ ID NO: 45). In some embodiments, the primer combination comprising HemB-FWD-B (SEQ ID NO: 35) and HemB-REV-D (SEQ ID NO: 45) is coupled to the probe sequence HemB-probe-C (SEQ ID NO: 55).
[0474] In some embodiments, the primer combination comprises HemB-FWD-A (SEQ ID NO: 33) and HemB-REV-A (SEQ ID NO: 39). In some embodiments, the primer combination comprising HemB-FWD-A (SEQ ID NO: 33) and HemB-REV-A (SEQ ID NO: 39) is coupled to the probe sequence HemB-probe-A (SEQ ID NO: 47).
[0475] In some embodiments, the primer combination comprises HemB-FWD-D (SEQ ID NO: 81) and HemB-REV-F (SEQ ID NO: 87). In some embodiments, the primer combination comprising HemB-FWD-D (SEQ ID NO: 81) and HemB-REV-F (SEQ ID NO: 87) is coupled to the probe sequence HemB-probe-E (SEQ ID NO: 89).
[0476] In some embodiments, the primer combination comprises HemB-FWD-B (SEQ ID NO: 35) and HemB-REV-C (SEQ ID NO: 43). In some embodiments, the primer combination comprising HemB-FWD-B (SEQ ID NO: 35) and HemB-REV-C (SEQ ID NO: 43) is coupled to the probe sequence HemB-probe-B (SEQ ID NO: 51).
[0477] In some embodiments, the primer combination comprises HemB-FWD-C (SEQ ID NO: 37) and HemB-REV-B (SEQ ID NO: 41). In some embodiments, the primer combination comprising HemB-FWD-C (SEQ ID NO: 37) and HemB-REV-B (SEQ ID NO: 41) is coupled to the probe sequence HemB-probe-D (SEQ ID NO: 59).
[0478] In some embodiments, the primer combination comprises HemB-FWD-C (SEQ ID NO: 37) and HemB-REV-B (SEQ ID NO: 41). In some embodiments, the primer combination comprising HemB-FWD-C (SEQ ID NO: 37) and HemB-REV-B (SEQ ID NO: 41) is coupled to the probe sequence HemB-probe-D (SEQ ID NO: 59).
[0479] In some embodiments, the primer combination comprises HemB-FWD-E (SEQ ID NO: 83) and HemB-REV-F (SEQ ID NO: 85). In some embodiments, the primer combination comprising HemB-FWD-E (SEQ ID NO: 83) and HemB-REV-F (SEQ ID NO: 85) is coupled to the probe sequence HemB-probe-E (SEQ ID NO: 89).
[0480] Oligonucleotide preparation
[0481] Oligonucleotides of the present disclosure can be prepared by any of a variety of methods (see, e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual", 1989, 2nd edition, Cold Spring Harbour Laboratory Press: New York, NY; "PCR Protocols: A Guide to Methods and Applications", 1990, Innis (ed.), Academic Press: New York, NY; Tijssen "Hybridization with Nucleic Acid Probes—Laboratory Techniques in Biochemistry and Molecular Biology (Parts I and II)", 1993, Elsevier Science; "PCR Strategies", 1995, Innis (ed.), Academic Press: New York, NY; and "Short Protocols in Molecular Biology", 2002, Ausubel (ed.), 5th edition, John Wiley & Sons: Secaucus, NJ).
[0482] In some embodiments, oligonucleotides can be prepared by chemical techniques well known in the art, including, for example, template-based chemical synthesis and polymerization, as described, for example, in Narang et al., Meth. Enzymol. 68:90-98 (1979); Brown et al., Meth. Enzymol. 68:109-151 (1979); Belousov et al., Nucleic Acids Res. 25:3440-3444 (1997); Guschin et al., Anal. Biochem. 250:203-211 (1997); Blommers et al., Biochemistry 33:7886-7896 (1994); Frenkel et al., Free Radic. Biol. Med. 19:373-380 (1995); and in U.S. Pat. No. 4,458,066.
[0483] In some embodiments, oligonucleotide can be prepared using the automated solid phase procedure based on the phosphoramidite method. In such methods, each nucleotide is added individually to the 5'-end of the growing oligonucleotide chain, which is attached to a solid support at the 3'-end. The added nucleotide is in the form of trivalent 3'-phosphoramidites, which are protected from polymerization by dimethoxy tri-base (or DMT) groups at the 5'-position. After the phosphoramidite coupling induced by the base, gentle oxidation is removed to obtain pentavalent phosphotriester intermediates and DMT to provide new sites for oligonucleotide extension. The oligonucleotide is then cut off from the solid support, and phosphodiester and exocyclic amino groups are deprotected with ammonium hydroxide. These synthesis can be carried out on an oligonucleotide synthesizer (such as those commercially available from Perkin Elmer / Applied Biosystems, Inc. (Foster City, CA), DuPont (Wilmington, DE) or Milligen (Bedford, MA)). Alternatively, oligonucleotides can be custom made and ordered from a variety of commercial sources well known in the art, including, for example, Midland Certified Reagent Company (Midland, TX), ExpressGen, Inc. (Chicago, IL), Operon Technologies, Inc. (Huntsville, AL), and many others.
[0484] Where necessary or desired, purification of oligonucleotides can be implemented by any of the various methods well known in the art. For example, purification of oligonucleotides is typically implemented by native acrylamide gel electrophoresis, by anion exchange HPLC (e.g., see Pearson and Regnier, J. Chrom. 255: 137-149 (1983)) or by reversed-phase HPLC (e.g., see McFarland and Borer, Nucleic Acids Res. 7: 1067-1080 (1979)).
[0485] The sequence of the oligonucleotide can be verified using any suitable sequencing method, including but not limited to chemical degradation (see, e.g., Maxam and Gilbert, Methods of Enzymology, 65:499-560 (1980)), matrix-assisted laser adsorption ionization time-of-flight (MALDI-TOF) mass spectrometry (see, e.g., Pieles et al., Nucleic Acids Res. 21:3191-3196 (1993)), mass spectrometry followed by a combination of alkaline phosphatase and exonuclease digestion (see, e.g., Wu and Aboleneen, Anal. Biochem. 290:347-352 (2001)).
[0486] The present disclosure encompasses modified forms of these oligonucleotides, which are carried out as equivalents of these oligonucleotides according to the method disclosed herein. Any of several methods known in the art can be used to prepare the oligonucleotides of these modifications. The limiting examples of this type of modification include methylation, "capping", replacing one or more naturally occurring nucleotides and internucleotide modifications with analogs, such as, for example, those with uncharged bonds (such as methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.) or charged bonds (such as, thiophosphates, phosphorodithioates, etc.). The oligonucleotide of the modification can also be derived by forming methyl or ethyl phosphotriesters or alkyl phosphoramidate bonds. In addition, the oligonucleotide of the present disclosure can also be modified with markers.
[0487] Oligonucleotide labeling
[0488] In some embodiments, the primer is labeled with a detectable agent or part before being used in the amplification / detection assay. The effect of the detectable agent is to allow visualization and detection of the amplified sequence. Preferably, the detectable agent is selected so that it generates a signal, and the signal is measurable and its intensity is related to (e.g., proportional to) the amount of the amplified product in the analyzed sample.
[0489] The association between the oligonucleotide and the detectable agent can be covalent or non-covalent. The detection primer of the label can be prepared by incorporating a detectable portion or being conjugated to a detectable portion. The label can be attached to the nucleic acid sequence directly or indirectly (e.g., via a joint). Joints or spacers of various lengths are known in the art and are commercially available, and can be selected to reduce steric hindrance, or to impart other useful or desired properties to the resulting labeled molecule, for example, see Mansfield et al., Mol. Cell Probes 9: 145-156 (1995).
[0490] Various methods for labeling nucleic acid molecules are known in the art. For a review of labeling protocols, label detection techniques, and the latest developments in the art, see, for example, Kricka, Ann. Clin. Biochem. 39: 114-129 (2002); van Gijlswijk et al., Expert Rev. Mol. Diagn. 1: 81-91 (2001); and Joos et al., J. Biotechnol. 35: 135-153 (1994). Standard nucleic acid labeling methods include: incorporation of radioactive agents, direct attachment of fluorescent dyes (Smith et al., Nucl. Acids Res. 13:2399-2412 (1985)) or enzymes (Connoly and Rider, Nucl. Acids Res. 13:4485-4502 (1985)); chemical modification of nucleic acid molecules (making them detectable by immunochemical or other affinity reactions) (see, e.g., Broker et al., Nucl. Acids Res. 5:363-384 (1978); Bayer et al., Methods of Biochem. Analysis 26:1-45 (1980); Langer et al., Proc. Natl. Acad. Sci. USA 78:6633-6637 (1981); Richardson et al., Nucl. Acids Res. 11:6167-6184 (1983); Brigati et al., Virol. 126:32-50 (1983); Tchen et al., Proc. Natl. Acad. Sci. USA 81:3466-3470 (1984); Landegent et al., Exp. Cell Res. 15:61-72 (1984); and Hopman et al., Exp. Cell Res. 169:357-368 (1987)); and enzyme-mediated labeling methods, such as random priming, nick translation, PCR, and tailing with terminal transferase. For a review of enzymatic labeling, see, eg, Temsamani and Agrawal, Mol. Biotechnol. 5:223-232 (1996).Recently developed nucleic acid labeling systems include, but are not limited to, ULS (Universal Ligation System), which is based on the reaction of a monoreactive cisplatin derivative with the N7 position of the guanine moiety in DNA (Heetebrij et al., Cytogenet. Cell. Genet. 87:47-52 (1999)), psoralen-biotin, which is intercalated into nucleic acids and becomes covalently bonded to nucleotide bases upon ultraviolet irradiation (Levenson et al., Methods Enzymol. 184:577-583 (1990); and Pfannschmidt et al., Nucleic Acids Res. 24:1702-1709 (1996)), photoreactive azide derivatives (Neves et al., Bioconjugate Chem. 11:51-55 (2000)), and DNA alkylating agents (Sebestyen et al., Nat. Biotechnol. 16:568-576 (1998)).
[0491] It will be appreciated that any of a variety of detectable agents may be used in the practice of the present disclosure. Suitable detectable agents include, but are not limited to, various ligands, radionuclides (such as, for example, 32 P. 35 S. 3 H. 14 C. 125 I. 131 I, etc.); fluorescent dyes (such as, for example, FAM, Yakima SUN TM 、HEX、 3. Texas and / or 5); fluorescent dye quencher (such as, for example, ZEN, IowaBlack TM FQ, IowaBlackRQ and / or TAO), chemiluminescent agents (such as, for example, acridinium esters, stable dioxetanes, etc.); spectrally resolvable inorganic fluorescent semiconductor nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver, copper, and platinum) or nanoclusters; enzymes (such as, for example, those used in ELISA, e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase); colorimetric labels (such as, for example, dyes, colloidal gold, etc.); magnetic labels (e.g., Dynabeads TM ); and biotin, dioxigenin or other haptens and proteins for which antisera or monoclonal antibodies are available.
[0492] A "tail" of normal or modified nucleotides may also be added to label the oligonucleotide for detectability purposes. In some embodiments, an M13 tag sequence may be added.
[0493] Extraction and preparation of viral oligonucleotides from biological samples
[0494] In some embodiments, the materials and methods of the present disclosure may include oligonucleotides extracted and prepared from biological samples. In some embodiments, suitable biological samples for extracting oligonucleotides include, but are not limited to, urine, semen, plasma, feces, whole blood, and / or saliva. Extraction and preparation of oligonucleotides from biological samples can be performed by methods generally known in the art (e.g., kPCR sample preparation 1.0 and / or 1.2) is performed.
[0495] Amplification methods and reactions
[0496] In some embodiments, the present disclosure provides methods for using the above oligonucleotides as amplification primers to amplify regions of specific AAV constructs, particularly regions not found in natural AAV and specific to certain therapeutic AAVs. As discussed in more detail below, in some embodiments, the primers are used in quantitative PCR methods for amplifying and detecting specific AAV constructs.
[0497] The use of the oligonucleotide sequences disclosed herein as primers for amplifying AAV target sequences in test samples is not limited to any specific nucleic acid amplification technique or any specific modification thereof. In fact, the oligonucleotide sequences of the present invention can be used in any of the various nucleic acid amplification methods well known in the art (see, for example, Kimmel and Berger, Methods Enzymol. 152: 307-316 (1987); Sambrook et al., "Molecular Cloning: A Laboratory Manual", 1989, 2nd edition, Cold Spring Harbour Laboratory Press: New York, NY; "Short Protocols in Molecular Biology", Ausubel (Ed.), 2002, 5th edition, John Wiley & Sons: Secaucus, NJ).
[0498] Such nucleic acid amplification methods include, but are not limited to, the polymerase chain reaction (or PCR, described in, e.g., “PCR Protocols: A Guide to Methods and Applications”, Innis (ed.), 1990, Academic Press: New York; “PCR Strategies”, Innis (ed.), 1995, Academic Press: New York; “Polymerase chain reaction: basic principles and automation in PCR: A Practical Approach”, McPherson et al. (eds.), 1991, IRL Press: Oxford; Saiki et al., Nature 324:163 (1986); and U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,889,818 (each of which is incorporated herein by reference in its entirety)); and reverse transcriptase polymerase chain reaction (or RT-PCR, described in, e.g., U.S. Pat. Nos. 5,322,770 and 5,310,652).
[0499] PCR (or polymerase chain reaction) technology is well known in the art and has been disclosed, for example, in Mullis and Faloona, Methods Enzymol., 155:350-355 (1987). In its simplest form, PCR is an in vitro method for enzymatically synthesizing a specific DNA sequence using two primers that hybridize to opposite strands and flank a region of interest in the target DNA. Multiple reaction cycles (each cycle includes: denaturation step, annealing step and polymerization step) lead to exponential accumulation of specific DNA fragments, see, for example, "PCR Protocols: A Guide to Methods and Applications", Innis (ed.), 1990, Academic Press: New York; "PCR Strategies", Innis (ed.), 1995, Academic Press: New York; "Polymerase chain reaction: basic principles and automation in PCR: A Practical Approach", McPherson et al. (ed.), 1991, IRL Press: Oxford; Saiki et al., Nature 324: 163-166 (1986). The end of the amplified fragment is defined as the 5' end of the primer. Examples of DNA polymerases capable of producing an amplified product in a PCR reaction include, but are not limited to, E. coli DNA polymerase I, Klenow fragment of DNA polymerase I, T4 DNA polymerase, a thermostable DNA polymerase isolated from Thermus aquaticus (Taq), which can be obtained from various sources (e.g., Perkin Elmer), Thermus thermophilus (United States Biochemicals), Bacillus stearothermophilus (Bio-Rad), or Thermococcus marina ("Vent" polymerase, New England Biolabs). RNA target sequences can be amplified by reverse transcribing mRNA into cDNA and then performing PCR (RT-PCR), as described above. Alternatively, a single enzyme can be used for both steps, as described in U.S. Pat. No. 5,322,770.
[0500] The duration and temperature of each step of the PCR cycle and the number of cycles are usually adjusted according to the effective stringency requirements. The annealing temperature and timing are determined by the efficiency of the expected primer and template annealing and the degree of mismatch to be tolerated. The ability to optimize the reaction cycle conditions is fully within the knowledge of those of ordinary skill in the art. Although the number of reaction cycles may be different according to the detection analysis performed, it is usually at least 15, more usually at least 20, and may be up to 60 or higher. However, in many cases, the number of reaction cycles usually ranges from about 20 to about 40.
[0501] The denaturation step of the PCR cycle typically includes heating the reaction mixture to an elevated temperature and maintaining the mixture at an elevated temperature for a period of time sufficient to dissociate any double-stranded or hybridized nucleic acids present in the reaction mixture. For denaturation, the temperature of the reaction mixture is typically raised to and maintained at a temperature ranging from about 85°C to about 100°C, typically from about 90°C to about 98°C, and more typically from about 90°C to about 94°C for a period of time ranging from about 3 to about 120 seconds, typically from about 5 to about 30 seconds. In some embodiments, the first cycle is preceded by an extended denaturation step ranging from about 1 to 10 minutes, typically from about 2 to 5 minutes.
[0502] After denaturation, the reaction mixture is subjected to conditions sufficient to anneal the primers to the template DNA present in the mixture. The temperature of the reaction mixture is typically selected to achieve these conditions to provide optimal efficiency and specificity, and typically ranges from about 45° C. to about 75° C., typically from about 50° C. to about 70° C., and more typically from about 53° C. to about 55° C. Annealing conditions are typically maintained for a period of time ranging from about 15 seconds to about 30 minutes, typically from about 30 seconds to about 1 minute.
[0503] After or during the annealing of the primer to the template DNA, the reaction mixture is subjected to conditions sufficient to provide conditions for polymerizing nucleotides to the end of the primer in a manner that extends the primer in the 5' to 3' direction using the DNA hybridized thereto as a template (i.e., conditions sufficient to enzymatically produce primer extension products). In order to achieve primer extension conditions, the temperature of the reaction mixture is typically raised to a temperature ranging from about 65°C to about 75°C, typically about 67°C to about 73°C, and maintained at this temperature for a period of time ranging from about 15 seconds to about 20 minutes, typically about 30 seconds to about 5 minutes. In some embodiments, the final extension step is followed by an extended extension step ranging from about 1 to 10 minutes, typically about 2 to 5 minutes.
[0504] The above-mentioned cycles of denaturation, annealing and polymerization can be performed using an automated device commonly referred to as a thermo-cycler or thermocycler. The thermocyclers that can be used are described in U.S. Patent Nos. 5,612,473; 5,602,756; 5,538,871; and 5,475,610. The thermocyclers are commercially available from, for example, Perkin Elmer-Applied Biosystems (Norwalk, CT), BioRad (Hercules, CA), Roche Applied Science (Indianapolis, IN), and Stratagene (LaJolla, CA).
[0505] In some embodiments, one or more of the PCR reactions is "kinetic PCR" (kPCR) or "kinetic RT-PCR" (kRT-PCR), which are also referred to as "real-time PCR" and "real-time RT-PCR," respectively. These methods involve detecting PCR products via probes that provide a signal (usually a fluorescent signal) that correlates with the amount of amplified product in the sample. Examples of probes commonly used in kPCR and kRT-PCR include the following probes: Probe, Molecular Beacon probe, Probe and Green probe. In short, Probes, MolecularBeacons, and The probes each have a fluorescent reporter dye (also called a "fluorescer") attached to the 5' end of the probe and a quencher moiety coupled to the 3' end of the probe. In the unhybridized state, the proximity of the fluorescent and quencher molecules prevents detection of the fluorescent signal from the probe. During PCR, as the polymerase replicates the template to which the probe is bound, the 5'-nuclease activity of the polymerase cleaves the probe, thereby increasing fluorescence with each replication cycle. The Green probe binds to double-stranded DNA and emits light upon excitation; thus, as PCR product accumulates, fluorescence increases.
[0506] In some embodiments, the PCR reaction is used in a "singleplex" PCR assay. "Singleplex" refers to a single assay that is not performed simultaneously with any other assay. A singleplex assay includes a single assay performed sequentially.
[0507] In some embodiments, the PCR reaction is used in a "multiplex" PCR assay. The term "multiplex" refers to multiple assays performed simultaneously, wherein the detection and analysis steps are typically performed in parallel. In the context of the present disclosure, a multiplex assay will include the use of primers alone or in combination with additional primers that identify, for example, an internal control or HCV virus variant and one or more additional HCV variants or other viruses.
[0508] In some embodiments, the first amplification step amplifies a region of the target gene. In some embodiments, the amplified product is less than about 1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600, 500, 400, 300, 250, 225, 200, 175, 150, 125, 100, or 75 nucleotides long.
[0509] Detection of amplification products
[0510] Amplification products produced using the oligonucleotides and methods of the present disclosure can be detected using various methods known in the art.
[0511] In some embodiments, amplification products can be detected simply using agarose gel electrophoresis and visualization by ethidium bromide staining and exposure to ultraviolet (UV) light.
[0512] In some embodiments, the presence of a specific genotype can be shown by restriction enzyme analysis. For example, a specific nucleotide polymorphism can result in a nucleotide sequence comprising a restriction site that does not exist in the nucleotide sequence of another allelic variant. Additionally or alternatively, a specific nucleotide polymorphism can result in the elimination of a nucleotide sequence comprising a restriction site that does not exist in the nucleotide sequence of another allelic variant.
[0513] Examples of techniques for detecting the difference of at least one nucleotide between two nucleic acids include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, an oligonucleotide probe can be prepared in which a known polymorphic nucleotide is placed in the center, and then hybridized with a target DNA under conditions where hybridization is allowed only when a perfect match is found, for example, see Saiki et al., Nature 324: 163 (1986); Saiki et al., Proc. Natl Acad. Sci USA 86: 6230 (1989); and Wallace et al., Nucl. Acids Res. 6: 3543 (1979). Such specific oligonucleotide hybridization techniques can be used to simultaneously detect several nucleotide changes in different polymorphic regions of DNA. For example, an oligonucleotide with a nucleotide sequence of a specific allelic variant is attached to a hybridization membrane, and then the membrane is hybridized with a labeled sample nucleic acid. The analysis of the hybridization signal will then reveal the identity of the nucleotides of the sample nucleic acid. Alternatively, an unlabeled sample nucleic acid can be fixed and contacted with a labeled oligonucleotide, which selectively hybridizes with a specific allelic variant.
[0514] Real-time pyrophosphate DNA sequencing is another method for detecting polymorphisms and polymorphic variants, for example, see Alderborn et al., Genome Research, 10 (8): 1249-1258 (2000). Additional methods include, for example, a combination of PCR amplification and denaturing high performance liquid chromatography (dHPLC), for example, see Underhill et al., Genome Research, 7 (10): 996-1005 (1997).
[0515] In some embodiments, any of the various sequencing reactions known in the art can be used to directly sequence at least a portion of the amplified DNA and detect allelic variants. The sequence can be compared with the sequence of known allelic variants to determine which allelic variants are present in the sample. Exemplary sequencing reactions include those based on Maxam and Gilbert, Proc. Natl. Acad. Sci USA, 74: 560 (1977) or Sanger, Proc. Nat. Acad. Sci 74: 5463 (1977) technology developed. It is also contemplated that any of a variety of automated sequencing programs may be utilized when performing the subject assay, see, e.g., Venter et al., Science, 291: 1304-1351 (2001); Lander et al., Nature, 409: 860-921 (2001), including sequencing by mass spectrometry, see, e.g., U.S. Patent No. 5,547,835 and PCT Patent Publication Nos. WO94 / 16101 and WO 94 / 21822; U.S. Patent No. 5,605,798 and PCT Patent Application No. PCT / US96 / 03651; Cohen et al., Adv. Chromatogr. 36: 127-162 (1996); and Griffin et al., Appl. Biochem. Biotechnol. 38: 147-159 (1993). It will be apparent to those skilled in the art that, for some embodiments, only one, two, or three occurrences of the nucleic acid bases need to be determined in the sequencing reaction. Still other sequencing methods are disclosed, for example, in U.S. Pat. Nos. 5,580,732; 5,571,676; 4,863,849; 5,302,509; PCT Patent Application Nos. WO 91 / 06678 and WO 93 / 21340; Canard et al., Gene 148:1-6 (1994); Metzker et al., Nucleic Acids Research 22:4259-4267 (1994) and U.S. Pat. Nos. 5,740,341 and 6,306,597.
[0516] In some embodiments, the detection of the amplicon is performed using real-time PCR. Real-time PCR has been developed to quantify the amplification product during the PCR reaction. Real-time PCR is based on such a principle: the fluorescence emission from the dye directly or indirectly associated with the formation of the newly synthesized amplicon or the annealing of the primer to the DNA template can be detected, and is directly proportional to the amount of the amplicon in each PCR cycle. Real-time PCR is implemented in a closed tube format and is quantitative. Several methods are currently available for performing real-time PCR, such as using TaqMan probes (U.S. Pat. Nos. 5,210,015 and 5,487,972, and Lee et al., Nucleic Acids Res. 21:3761-6, 1993), molecular beacons (U.S. Pat. Nos. 5,925,517 and 6,103,476, and Tyagi and Kramer, Nat. Biotechnol. 14:303-8, 1996), self-detecting amplicons (scorpions) (U.S. Pat. No. 6,326,145 and Whitcombe et al., Nat. Biotechnol. 17:804-7, 1999), Amplisensor (Chen et al., Appl. Environ. Microbiol. 64:4210-6, 1998), Amplifluor (U.S. Pat. No. 117,635, and Nazarenko et al., Nucleic Acids Res.25:2516-21,1997), displacement hybridization probes (Li et al., Nucleic Acids Res.30:E5,2002), DzyNA-PCR (Todd et al., Clin. Chem.46:625-30,2000), fluorescent restriction enzyme detection (Cairns et al. Biochem. Biophys. Res. Commun.318:684-90,2004) and adjacent hybridization probes (U.S. Pat. No. 6,174,670 and Wittwer et al., Biotechniques 22:130-1,134-8,1997). Most of these probes consist of a pair of dyes (reporter dye and acceptor dye) that participate in fluorescence resonance energy transfer (FRET), in which the acceptor dye quenches the emission of the reporter dye. Typically, fluorescently labeled probes increase the specificity of amplicon quantification.
[0517] In some embodiments, detection of amplicons is performed using real-time PCR in conjunction with a TaqMan assay. U.S. Patent Nos. 5,210,015 and 5,487,972 describe a 5' nuclease assay, also referred to as a TaqMan assay. The TaqMan assay utilizes the 5' nuclease activity of TaqDNA polymerase to cleave a TaqMan probe during PCR. The TaqMan probe contains a reporter dye at the 5' end of the probe and a quencher dye at the 3' end of the probe. During the reaction, cleavage of the probe separates the reporter dye and the quencher dye, resulting in an increase in the fluorescence of the reporter. Accumulation of PCR products is detected directly by monitoring the increase in fluorescence of the reporter dye. When the probe is intact, the close proximity of the reporter dye to the quencher dye results in the expression of the quencher dye primarily through Inhibition of reporter fluorescence of type energy transfer ( 1948; Lakowicz, 1983). During PCR, if the target of interest is present, the probe anneals specifically between the forward and reverse primer sites. Only when the probe hybridizes to the target does the 5' to 3' nucleolytic activity of Taq DNA polymerase cleave the probe between the reporter and the quencher. The probe fragment then moves away from the target, and polymerization of the chain continues. The 3' end of the probe is blocked to prevent the probe from extending during PCR. This process occurs in each cycle and does not interfere with the exponential accumulation of product.
[0518] Compositions and kits
[0519] In some embodiments, the disclosure provides kits comprising materials that can be used to amplify and detect or sequence specific AAV constructs according to the methods described herein. The kits of the invention can be used by diagnostic laboratories, experimental laboratories, or practitioners.
[0520] Materials and reagents that can be used for detection or sequencing of specific AAV constructs according to the present disclosure can be assembled together in a kit. In some embodiments, the kit of the present invention comprises at least one primer set of the present invention, and optionally reverse transcription and / or amplification reaction reagents. In some embodiments, the kit comprises reagents that make the procedure specific. Therefore, a kit intended for detecting a specific specific AAV construct variant preferably comprises a primer set as described herein, which can be used to amplify a specific specific target AAV construct target sequence. A kit intended for multiple detection of multiple specific AAV construct target sequences and / or other viruses preferably comprises a plurality of primer sets as described herein (optionally in separate containers), which can be used to amplify a specific AAV construct target sequence as described herein.
[0521] Suitable reverse transcription / amplification reaction reagents that can be included in the kits of the present invention include, for example, one or more of the following: a buffer; an enzyme having reverse transcriptase and / or polymerase activity; an enzyme cofactor, such as magnesium or manganese; a salt; nicotinamide adenosine dinuclease (NAD); and deoxynucleoside triphosphates (dNTPs), such as, for example, deoxyadenosine triphosphate; deoxyguanosine triphosphate, deoxycytidine triphosphate and deoxythymidine triphosphate, biotinylated dNTPs, which are suitable for carrying out an amplification reaction.
[0522] Depending on the procedure, the kit may further comprise one or more of: washing buffer and / or reagents, hybridization buffer and / or reagents, labeling buffer and / or reagents and detection means. The buffer and / or reagents included in the kit are preferably optimized for the specific amplification / detection technology expected by the kit. Protocols for using these buffers and reagents to carry out the different steps of the procedure may also be included in the kit.
[0523] Furthermore, the kit may be provided with an internal control to check the amplification procedure and prevent false negative test results due to failure of the amplification procedure.The optimal control sequence is selected (as described above) in such a way that it does not compete with the target nucleic acid sequence in the amplification reaction.
[0524] The kit may also contain reagents for isolating nucleic acids from a biological sample prior to amplification and / or for purifying or isolating AAV particles prior to nucleic acid extraction.
[0525] The reagents can be provided in solid (e.g., lyophilized) or liquid form. The kit of the present disclosure optionally includes different containers (e.g., vials, ampoules, test tubes, flasks or bottles) for each separate buffer and / or reagent. Each component is generally suitable for being equally divided in its respective container or provided in a concentrated form. Other containers suitable for carrying out certain steps of amplification / detection assays can also be provided. Each container of the kit is preferably kept in a confined space for commercial sale.
[0526] The kit may also include instructions for using the amplification reaction reagents and primer sets or primer / probe sets according to the present disclosure. Instructions for using the kit according to one or more methods of the present disclosure may include instructions for processing biological samples, extracting nucleic acid molecules and / or performing tests; instructions for interpreting the results and notifications in a form specified by a government agency (e.g., FDA) that regulates the manufacture, use or sale of drugs or biological products.
[0527] The present disclosure is further described in detail by reference to the following experimental examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise indicated. Therefore, the present disclosure should never be interpreted as being limited to the following examples, but should be interpreted as covering any and all variations that become apparent due to the teachings provided herein.
[0528] For example, other assays, including those described in the Examples section herein and those known in the art, may also be used in accordance with the present disclosure.
[0529] Example
[0530] Reagents, equipment, methods and consumables for direct examples -
[0531] Reagents
[0532]
[0533] Equipment and consumables
[0534]
[0535]
[0536] Example 1: General Method
[0537] This example provides an overview of a number of generalizable assays and / or processes utilized during sample preparation and quantitation.
[0538] MNase treatment - MNase treatment procedures were performed prior to sample extraction and were in accordance with manufacturer recommendations.
[0539] Quantification of AAV shedding assay by qPCR - 5 μL of DNA extract was used to test the extracted DNA in a qPCR reaction. The concentration of AAV viral DNA in the samples was determined by plotting their Ct values against the Ct values obtained from AAV viral calibrators extracted from buffer of known concentration. QuantStudio TM 7 Flex or Dx Real-Time PCR System was used for qPCR analysis. The concentration of AAV viral DNA in plasma, urine, semen, and saliva samples was reported as viral genomes (vg) / mL, and the concentration of AAV viral DNA in PBMC samples was reported as viral genomes (vg) / 1 μg genomic DNA.
[0540] Sample preparation for AAV shedding assay - according to The kPCR Molecular System - Stand-Alone Sample Preparation Module (SASP) prepares samples using a viral DNA extraction and purification process. Viral DNA samples were isolated and purified for use in the amplification procedure according to the manufacturer's instructions.
[0541] Example 2: Identification and optimization of primers for quantification of shedding in Duchenne muscular dystrophy AAV gene therapy.
[0542] This example demonstrates the utility, accuracy, sensitivity and precision of assays using the oligonucleotide sequences described herein. This shedding assay detects and quantifies exemplary viral DNA (e.g., exemplary DMD AAV constructs) extracted from urine, whole blood, feces and saliva. The exemplary DMD AAV construct is an adeno-associated virus encoding a micro-dystrophin protein.
[0543] 5 μL of DNA extract was used to test the extracted DNA in a qPCR reaction. The Ct values of the exemplary DMD AAV construct virus calibrators extracted in buffer were compared to their known concentrations (log-transformed, see Figure 2 ) plotted to generate a linear regression curve. The concentration of exemplary DMD AAV construct viral DNA in the sample was determined by fitting their Ct values in the model. The concentration of exemplary DMD AAV construct viral DNA in urine, whole blood and saliva samples was reported as viral genome number (vg) / mL, and the concentration of exemplary DMD AAV construct viral DNA in feces samples was reported as vg / mg.
[0544] Current FDA guidelines require that qPCR be able to detect <50 copies of vector / 1 μg genomic DNA with 95% confidence. The qPCR quantitative limit was determined using a set of linearized plasmids containing an exemplary DMD AAV construct viral genome incorporated into human genomic DNA. N=444 was selected for 25 copies of vector / 1 μg genomic DNA to ensure that a 95% detection rate with sufficient confidence could be achieved (outlined below).
[0545] Initial Screening of Exemplary Primers and / or Probes
[0546] Primers were designed targeting selected regions of exemplary DMD AAV constructs (see Figure 1 ). Prior to completing oligonucleotide characterization, at least one or more forward primers, at least one or more reverse primers, and at least one or more probes are screened for characteristics such as multiplex capacity, maximum fluorescence, slope, minimum CT, Tm, oligonucleotide cross-reactivity, and / or specificity for the DMD AAV construct in the presence of background genomic DNA.
[0547] Determine that some primer and probe combination works well under the assay conditions of test.As shown in the drawings and further shown in this paper, some primer and probe combination provides the expected overview.However, the primer and / or probe combination of substitution can be screened as shown to determine the expected overview for other conditions, samples, etc., and the disclosure recognizes that multiple primers and / or probe combination may be applicable to accurate and reliable detection and / or quantitative.Data also confirm that selected primer and probe combination works well when (for example, with internal control primer and probe combination) multiplexing.In some embodiments, those skilled in the art will understand that some features may be more or less desired, and the selection of a group of primers and probes for specific applications may depend on weighing some features, such as multiplexing capability, maximum fluorescence, slope, minimum CT, Tm, oligonucleotide cross-reactivity, in the presence of background genomic DNA to the specificity of DMD AAV construct or all or all or any combination of these factors.Nevertheless, the data provided herein have established that disclosed primers and / or probe work well for detecting the AAV construct in biological samples. At least one or more forward primers, at least one or more reverse primers, and at least one or more probes are found to be suitable for one or more initial screening criteria (see, eg, Table 1, Table 2, and Figures 17-19).
[0548] Table 1 - Initial screening of certain oligonucleotide combinations targeting replacement regions of exemplary DMD AAV constructs
[0549]
[0550] Table 1 (continued)
[0551]
[0552] Table 2 - Initial screening of certain multiplex assays used for exemplary DMD AAV constructs
[0553]
[0554] Table 2 (continued)
[0555]
[0556] Data calculation and reporting
[0557] The observed data were fitted with the following nonlinear regression model:
[0558] Accuracy = β0 + β1 × e (β2×log10(观察浓度)) +ε
[0559] where β0, β1 and β2 are the coefficients of the model and ε is the random error term. JMP (version 14.1, SAS Institute) was used for calculations using the exponential 3P fit curve model.
[0560] The lower limit of quantitation (LLoQ) using the precision curve method was calculated as the concentration at the 95% upper confidence limit of the fitted curve at 20% CV.
[0561] Based on the criteria of ≥95% detection, ≤20% variability, and difference within 0.125LOG from the target value, the lower limit of quantification (LLoQ) of qPCR was determined to be 50 viral genome copies / 1μg genomic DNA, exceeding the FDA guidance requirements.
[0562] The shedding assay detection range is summarized below. If the titer is detected as above the upper limit of quantitation, the sample is reported as ALQ (above the limit of quantitation); if the titer is determined to be below the lower limit of quantitation, the sample is reported as BLQ (below the limit of quantitation); and if the titer is within the quantitation range, a numerical concentration is reported.
[0563] Using QuantStudio TM 7 Flex and QuantStudio TM Software v1.1 determines the original signal of exemplary DMD AAV construct whole blood, saliva, feces and urine.The concentration of exemplary DMD AAV construct is calculated using a linear regression curve, which is generated by plotting the Ct value of the exemplary DMD AAV construct virus calibrator extracted in the buffer for its known concentration (logarithmic conversion).The concentration of exemplary DMD AAV construct viral DNA in the sample is determined by fitting the Ct value in the model. This is completed in Microsoft Excel, Microsoft Office 363 Pro version 1909. For tables, final concentration is reported with viral genome (vg) / mL, except feces, which is reported with vg / mg, at least three significant figures. Accuracy (%CV) is reported as the nearest 0.1%.
[0564] Statistical analysis
[0565] Accuracy-Titer data were considered to be lognormally distributed and analyzed after log10 transformation. The exemplary DMD AAV construct shedding assay accuracy was determined using the same set described in the analytical sensitivity section below. Accuracy was calculated by the difference between the observed and expected values after logarithmic transformation, and the target requirement was within ±0.5 log deviation of the expected value within the quantitative range. The exemplary DMD AAV construct shedding assay linearity and accuracy for each sample type are summarized below.
[0566] Linearity - Assay linearity was assessed by fitting a linear regression model as follows
[0567] Log10(quantitative)=β0+β1×Log10(input concentration)+ε
[0568] Where β0 is the intercept, β1 is the slope, and ε is the random error term. Based on this model, the coefficient of determination R is calculated 2 If R 2 Above 0.95, linearity is established. Accuracy and linearity analyses were performed using R (version 3.5.12018-07-02, https: / / cran.rproject.org / ).
[0569] Precision – For each concentration level, the reproducibility or precision of the within-laboratory assay was estimated using the following variance component model,
[0570] Quantification = intercept + instrument + run + intra-run (error)
[0571] The instrument, run, and within-run errors were considered as random effects. The variance components were estimated using the random effects model. The total variance δ considering all inter-instrument, inter-run, and within-run effects was 2 is estimated as the sum of the individual variance components. The measure of reproducibility is the percentage coefficient of variation (%CV), or the total variance divided by the mean. Variance components were analyzed in JMP (version 13.1, SASInstitute) using the REML (restricted maximum likelihood) model (https: / / www.jmp.com / support / help / 14-2 / restricted-maximumlikelihood-reml-model.shtml).
[0572] Specificity - Assay specificity was calculated as the ratio of identified negative samples to all unspiked (true negative) samples. Assay specificity for exemplary DMD AAV construct shedding was determined with 20-24 biological replicates (20 for saliva, feces and urine, and 24 for whole blood) using normal human saliva, feces, urine and whole blood samples without any viral spike-in. Specificity was above 95% in all sample types tested.
[0573] Analytical Sensitivity - To measure analytical sensitivity, the observed data were fit to the following nonlinear regression model:
[0574] Precision = β0 + β1 × e^((β2 × log10(observed concentration))) + ε
[0575] where β0, β1 and β2 are the coefficients of the model and ε is the random error term. JMP (version 14.1, SAS Institute) was used for calculations using the exponential 3P fitting curve model.
[0576] The lower limit of quantitation (LLoQ) using the precision curve method was calculated as the concentration of the 95% upper confidence limit of the fitted curve at 30% CV.
[0577] Analytical sensitivity was determined in a two-step approach. In step 1, up to 12-replicate groups were tested on two different VERSANT kPCR extraction systems for saliva, feces, and urine to estimate the lower limit of quantification (LLoQ), and for blood, at least 6 replicates were tested each using only one VERSANT kPCR extraction system. In step 2, up to 36 biological replicates close to the estimated LLoQ level were used to further refine the LLoQ for all sample types. The concentration at the 95% confidence limit of the fitted curve within 30% CV and ± 0.5LOG deviation was determined as the LLoQ for that sample type. An exemplary DMD AAV construct shedding assay analytical sensitivity for each sample type is outlined below.
[0578] result:
[0579] Shedding assay performance summary - The shedding assay provides quantitative results for saliva, feces, urine, and whole blood samples within the respective assay ranges. The shedding assay detection range is summarized in Table 3. If the titer is monitored as being above the upper limit of quantitation, the sample is reported as AQL (above the limit of quantitation); if the titer is determined to be below the lower limit of quantitation, the sample is reported as BQL (below the limit of quantitation); and if the titer is within the quantitative range, a numerical concentration is reported.
[0580] Table 3: Performance evaluation overview
[0581] Matrix Lower limit of quantitation (LLOQ) Upper limit of quantitation (ULoQ) saliva 3.67E+03vg / mL 9.84E+08vg / mL stool 3.90E+01vg / mg 1.28E+07vg / mg Urine 4.26E+03vg / mL 1.14E+09vg / mL Whole blood 8.45E+03vg / mL 7.63E+08vg / mL .
[0582] DNase treatment performance overview - MNase treatment was selected as the nuclease for DNase treatment evaluation. MNase is a DNA and RNA endonuclease and is capable of cutting double-stranded DNA (dsDNA), single-stranded DNA (ssDNA) and RNA. MNase has higher activity than DNaseI (2,000,000 units / mL of MNase and 2,000 units / mL of DNaseI are commercially available through NewEngland Biolabs). Incomplete digestion of unprotected DNA was observed with DNaseI (up to 250 units, limited by reserve concentration) in the reaction buffer system. In contrast, in all sample types tested, MNase treatment with 4,000 units eliminated unprotected deoxynucleic acids (both dsDNA and ssDNA), and did not reduce the recovery of the exemplary Hem-B AAV construct from intact viral particles (see Example 3 below).
[0583] The effect of MNase treatment on the recovery of intact exemplary DMD AAV construct viral DNA was evaluated at concentrations close to LLoQ in all sample types except whole blood with a minimum of 12 replicates. No significant differences were observed between MNase treated or untreated samples for all sample types (see Tables 4 and 5 below). Figure 7 ). All measured differences were within the assay accuracy of + / - 0.5 log and the % variation was within the acceptable assay variation. MNase treatment of the linearized plasmid resulted in complete loss of DNA (CT not determined). MNase treatment is not suitable for whole blood as a sample type because the MNase buffer causes blood to coagulate (see Figure 8 ). DNase I does work well with whole blood collected in sodium citrate collection tubes, but has a strong negative impact on the calibration system that has been developed. Since whole blood is not considered a frequently shed body fluid, no effort was made to redevelop the calibration system for DNase I treated whole blood.
[0584] Table 4 - Overview of MNase treatment
[0585]
[0586] qPCR performance – FDA guidance requires that qPCR be able to detect <50 copies of vector / 1 μg genomic DNA with 95% confidence. qPCR quantification limits were determined using a set of linearized plasmids containing the viral genome of an exemplary DMD AAV construct spiked into human genomic DNA. N = 444 was chosen for 25 copies of vector / 1 μg genomic DNA to ensure that a 95% detection rate with adequate confidence could be achieved (outlined in Figure 3 and Tables 5 and 6).
[0587] Table 5 – Summary of analytical sensitivity results (LloQ)
[0588]
[0589] Table 6 – qPCR detection limits
[0590]
[0591] Accuracy - Titer data were considered to be lognormally distributed and analyzed after log10 transformation. Exemplary DMD AAV construct shedding assay accuracy was determined using the same sample set described above for analytical sensitivity. Accuracy was calculated by the difference between the observed and expected values after logarithmic transformation, and the target requirement was within ±0.5 logarithmic deviation of the expected value within the quantitative range. Exemplary DMD AAV construct shedding assay linearity and accuracy for each sample type are summarized and presented in Tables 7-10.
[0592] Table 7 - Accuracy Assessment of Shedding Assays for Exemplary DMD AAV Constructs in Saliva
[0593]
[0594]
[0595] Table 8 - Accuracy Assessment of Shedding Assays of Exemplary DMD AAV Constructs in Feces*
[0596]
[0597] *Feces were suspended in 10 volumes (w / v) of 1X PBS before extraction.
[0598] Table 9 - Accuracy Assessment of Shedding Assays for Exemplary DMD AAV Constructs in Urine
[0599]
[0600]
[0601] Table 10 - Accuracy evaluation of shedding assays of exemplary DMD AAV constructs in whole blood
[0602]
[0603] Specificity - Assay specificity was calculated as the ratio of identified negative samples to all unspiked (true negative) samples. Assay specificity for exemplary DMD AAV construct shedding was determined with 20-24 biological replicates (20 for saliva, feces and urine, and 24 for whole blood) using normal human saliva, feces, urine and whole blood samples without any viral spike-in. Specificity was above 95% in all sample types tested.
[0604] Analytical Sensitivity - Analytical sensitivity was determined in a two-step approach. In step 1, up to 12-replicate groups were tested on two different VERSANT kPCR extraction systems for saliva, feces, and urine to estimate the lower limit of quantification (LLoQ), and for blood, at least 6 replicates were tested each using only one VERSANT kPCR extraction system. In step 2, up to 36 biological replicates close to the estimated LLoQ level were used to further refine the LLoQ for all sample types. The concentration at the 95% upper confidence limit of the fitted curve within 30% CV and ±0.5LOG deviation was determined as the LLoQ for that sample type. Exemplary DMD AAV construct shedding assay analytical sensitivities for each sample type are summarized in Tables 11-14 below.
[0605] Table 11 - Analytical sensitivity and specificity of exemplary DMD AAV constructs in human saliva
[0606]
[0607] Table 12 - Analytical Sensitivity and Specificity of Exemplary DMD AAV Constructs in Human Feces*
[0608]
[0609] *Feces were suspended in 10 volumes (w / v) of 1X PBS before extraction.
[0610] Table 13 - Analytical sensitivity and specificity of exemplary DMD AAV constructs in human urine
[0611]
[0612] Table 14 - Analytical sensitivity and specificity of exemplary DMD AAV constructs in human whole blood
[0613]
[0614] Ambient Temperature, Repeated Freeze / Thaw, and Long-Term -80°C Storage Stability of PBMCs, Saliva, Urine, and Feces - The stability of exemplary DMD AAV construct viruses in PBMCs, saliva, feces, and urine was evaluated for storage at ambient temperature, long-term storage at -80°C for up to 6 months, and freeze-thaw cycles. Pooled samples (later 5E+6 cells / mL suspension of PBMCs and 1:10 (w:v) suspension of feces) were spiked at 1.0E+05 vg / mL, and three biological replicates of each condition were tested at the indicated time points. Exemplary DMD AAV construct viral genome titers were within ±0.5LOG of the titer measured at time 0 for up to 6 months. The long-term -80°C storage stability results are summarized in Figure 5 and Table 15. The ambient temperature stability is summarized in Figure 4 Freeze / thaw evaluation is outlined in Figure 6 middle.
[0615] Table 15 - Long-term stability of exemplary DMD AAV constructs stored and frozen at -80°C
[0616]
[0617] Example 3: Identification and optimization of primers for quantification of shedding in an exemplary hemophilia B AAV gene therapy.
[0618] This example shows the effectiveness, accuracy, sensitivity and precision of the determinations performed using oligonucleotide sequences described herein. This fall-off assay detects and quantifies exemplary viral DNA (e.g., exemplary Hem-B AAV constructs) extracted from urine, blood plasma, semen, whole blood, feces and saliva. The exemplary Hem-B AAV construct is an adeno-associated virus encoding factor IX. The extracted DNA was tested in qPCR reactions using 5 μL DNA extracts. The Ct values of the exemplary Hem-B AAV construct virus calibrators extracted in the buffer were plotted against their known concentrations (logarithmically transformed, see Figure 9) to generate a linear regression curve. The concentration of the exemplary Hem-B AAV construct viral DNA in the sample was determined by fitting their Ct values in the model. The concentration of the exemplary Hem-B AAV construct viral DNA in urine, blood plasma, semen, whole blood and saliva samples was reported as viral genome number (vg) / mL, and the concentration of the exemplary Hem-B AAV construct viral DNA in feces samples was reported as vg / mg.
[0619] FDA guidelines require that qPCR be able to detect <50 copies of vector / 1μg genomic DNA with 95% confidence. The qPCR quantitative limit was determined using a set of linearized plasmids containing an exemplary Hem-BAAV construct viral genome incorporated into human genomic DNA. Different concentrations of linearized plasmids were tested with different numbers of replicates to evaluate the quantitative limit. N=75 was selected for the lowest concentration to ensure a 95% detection rate with sufficient confidence. Based on the criteria of ≥95% detection, ≤20% variability, and a difference from the target value within 0.125LOG, the lower limit of quantification (LLoQ) of qPCR was determined to be 31 viral genome copies / 1μg genomic DNA (outlined below).
[0620] This example demonstrates the utility, accuracy, sensitivity, and precision of assays performed using the oligonucleotide sequences described herein.
[0621] Initial Screening of Exemplary Primers and / or Probes
[0622] Primers targeting selected regions of exemplary HemB AAV constructs were designed (see Figure 1 ). Prior to completing oligonucleotide characterization, at least one or more forward primers, at least one or more reverse primers, and at least one or more probes are screened for characteristics such as multiplex capacity, maximum fluorescence, slope, minimum CT, Tm, oligonucleotide cross-reactivity, and / or specificity for the HemB AAV construct in the presence of background genomic DNA.
[0623] Determine that some primer and probe combination works well under the assay conditions of test.As shown in the drawings and further shown herein, some primer and probe combination provides the expected overview.However, the primer and / or probe combination of substitution can be screened as shown to determine the expected overview for other conditions, samples, etc., and the disclosure recognizes that multiple primers and / or probe combination may be applicable to accurate and reliable detection and / or quantification.Data also confirm that selected primer and probe combination works well when (for example, with internal control primer and probe combination) multiplexed.In some embodiments, those skilled in the art will appreciate that some features may be more or less desired, and the selection of a group of primers and probes for a specific application may depend on weighing some features, such as multiplexed capability, maximum fluorescence, slope, minimum CT, Tm, oligonucleotide cross-reactivity, in the presence of background genomic DNA to the specificity of HemB AAV construct or all or all or any combination of these factors.Nevertheless, the data provided herein establish that disclosed primers and / or probe work well for detecting the AAV construct in biological samples. At least one or more forward primers, at least one or more reverse primers, and at least one or more probes were found to be suitable for one or more of the initial screening criteria (see, e.g., Tables 16-18 and Figures 20-23 for certain results).
[0624] Table 16 - Initial Screening of Certain Oligonucleotide Combinations Targeting Replacement Regions of Exemplary HEM-B AAV Constructs
[0625]
[0626] Table 16 (continued)
[0627]
[0629] Table 17 - Initial screening of certain multiplex assay results for exemplary HEM-B AAV constructs
[0630]
[0631] Table 17 (continued)
[0632]
[0633] Table 18 - Certain primer / probe sets used to amplify and quantify exemplary Hem-B AAV constructs
[0634]
[0635]
[0636] Statistical analysis
[0637] Accuracy - Assay accuracy was determined by calculating the mean log recovery, defined as the mean difference between the observed mean log quantitation and the log input concentration (expected) of the test levels.
[0638] Linearity - Assay linearity was assessed by fitting a linear regression model as follows
[0639] Log10(quantitative)=β0+β1×Log10(input concentration)+ε
[0640] Where β0 is the intercept, β1 is the slope, and ε is the random error term. Based on this model, the coefficient of determination R is calculated 2 If R 2 Above 0.95, linearity is established. Accuracy and linearity analyses were performed using R (version 3.5.12018-07-02, https: / / cran.rproject.org / ).
[0641] Precision – For each concentration level, the reproducibility or precision of the within-laboratory assay was estimated using the following variance component model,
[0642] Quantification = intercept + instrument + run + intra-run (error)
[0643] where instrument, run, and within-run errors are considered as random effects. Variance components are estimated via a random effects model. Variance components are estimated via a random effects model. The total variance δ considering all between-instrument, between-run, and within-run effects is 2 is estimated as the sum of the individual variance components. The measure of reproducibility is the percent coefficient of variation (%CV), or the total variance divided by the mean. Variance components were analyzed in JMP (version 13.1, SAS Institute) using the REML (restricted maximum likelihood) model (https: / / www.jmp.com / support / help / 14-2 / restricted-maximumlikelihood-reml-model.shtml).
[0644] Specificity - Assay specificity was calculated as 1 minus the ratio of false positive samples to all unspiked (negative) samples.
[0645] Analytical sensitivity - the lower limit of quantitation (LLoQ) is the lowest input concentration that meets all of the above criteria with at least 95% detection.
[0646] result:
[0647] qPCR Performance Overview - The lower limit of quantitation (LLoQ) for qPCR was 31 copies of an exemplary Hem-B AAV construct viral DNA in a background of 1 μg genomic DNA.
[0648] Shedding assay performance summary - The shedding assay provides quantitative results for plasma, PBMC, saliva, semen, feces, and urine samples within the corresponding assay range. The shedding assay detection range is summarized in Table 19. If the titer is monitored as being above the upper limit of quantitation, the sample is reported as AQL (above the limit of quantitation); if the titer is determined to be below the lower limit of quantitation, the sample is reported as BQL (below the limit of quantitation); and if the titer is within the quantitative range, a numerical concentration is reported.
[0649] Table 19 – Summary of shedding assay detection range
[0650] Sample type Lower limit of quantitation (LLoQ) Upper limit of quantitation (ULoQ) plasma 1440vg / mL 1.0E+08vg / mL PBMC 316vg / 1μg genomic DNA 4.7E+07vg / 1μg genomic DNA saliva 6172vg / mL 1.3E+09vg / mL semen 6037vg / mL 1.5E+09vg / mL stool 25vg / mg 1.4E+07vg / mg feces Urine 5494vg / mL 1.4E+09vg / mL .
[0651] DNase treatment performance overview-MNase is a nuclease selected for DNase treatment. MNase acts as an effective DNA and RNA endonuclease, cutting double-stranded DNA (dsDNA), single-stranded DNA (ssDNA) and RNA. MNase is known to be more effective than DNaseI (MNase of 2,000,000 units / mL and DNaseI of 2,000 units / mL are commercially available through New England Biolabs). Incomplete digestion of unprotected DNA is observed with DNaseI (up to 250 units, limited by reserve concentration) in the reaction buffer system. In contrast, in all sample types tested, unprotected deoxynucleic acids (dsDNA and ssDNA) are eliminated with 4,000 units of MNase treatment, and the recovery of exemplary Hem-B AAV constructs from complete viral particles is not reduced.
[0652] qPCR Performance - FDA guidelines require that qPCR be able to detect <50 copies of vector / 1 μg genomic DNA with 95% confidence. The qPCR limit of quantification was determined by using a set of linearized plasmids at different concentrations, which contained exemplary Hem-B AAV construct viral genomes incorporated into human genomic DNA. Different concentrations of linearized plasmids were tested with different numbers of replicates to evaluate the limit of quantification. N=75 was selected for the lowest concentration to ensure 95% detection rate with sufficient confidence. Based on the criteria of ≥95% detection, ≤20% variability, and a difference from the target value within 0.125LOG, the lower limit of quantification (LLoQ) of qPCR was determined to be 31 viral genome copies / 1 μg genomic DNA (summarized in Table 20, exceeding the FDA guidance requirements.
[0653] Table 20 – Performance evaluation report overview
[0654]
[0655] The Siemens Healthineers SASP1.0 system is a scalable, automated and optimized multi-sample type preparation system that allows barcode tracking of samples and controls. The SASP 1.0 kit has increased precision for semen samples compared to the SASP 1.2 kit, and the optimized system allows batch processing of all six biological sample types within the same run, achieving a high degree of synergy for shedding assays.
[0656] Specificity - The specificity of the exemplary Hem-B AAV construct shedding assay was determined using 32 biological replicates each using normal human plasma, PBMC, urine, saliva, semen, and feces samples without any virus spiked in. In all sample types, 32 / 32 replicates were below the limit of quantitation and the specificity was 100% in all sample types tested.
[0657] Analytical Sensitivity - During the assignment process, the linearized plasmid was used as a standard in parallel with viral material diluted in viral storage buffer, processed by extraction and qPCR. Based on the linearized plasmid standard, the viral stock titer was determined to be 1.53E+13 vg / mL. The performance evaluation was performed in two steps. In step 1, for each sample type, 12 replicates were tested to estimate the lower limit of quantification (LLoQ); in step 2, up to 36 biological replicates close to the estimated LLoQ level were used to further refine the LLoQ. The lowest sample concentration demonstrated to have ≤30% CV and within ±0.5LOG of the bias was determined as the LLoQ for that sample type. Exemplary Hem-B AAV construct shedding assay analytical sensitivities for each sample type are summarized in Tables 21-26 below.
[0658] Table 21 - Analytical Sensitivity in Plasma
[0659]
[0660] Table 22 - Analytical Sensitivity in PBMC*
[0661]
[0662] *PBMCs were resuspended in cell freezing medium at a concentration of 5E+6 cells / mL.
[0663] Table 23 - Analytical Sensitivity in Saliva
[0664]
[0665] Table 24 - Analytical Sensitivity in Semen
[0666]
[0667] Table 25 - Analytical Sensitivity in Feces**
[0668]
[0669] **Feces were suspended in 10 volumes (w:v) of 1X PBS prior to extraction.
[0670] One sample was lost due to clogging.
[0671] Table 26 - Analytical Sensitivity in Urine
[0672]
[0673] Accuracy - Titer data were assumed to be log-normally distributed and analyzed after log10 transformation. Exemplary Hem-B AAV construct shedding assay accuracy was determined using the same sample set described above for analytical sensitivity. Accuracy was calculated by the difference between the observed and expected values after log transformation, and the target requirement was within ±0.5 log deviation of the expected value within the quantitative range. Exemplary Hem-B AAV construct shedding assay linearity and accuracy for each sample type are summarized and presented in Tables 27-32 and Figure 9.
[0674] Table 27 - Accuracy in plasma
[0675]
[0676] Table 28 - Accuracy in PBMC
[0677]
[0678]
[0679] *PBMCs were resuspended in cell freezing medium at a concentration of 5E+6 cells / mL.
[0680] Table 29 - Accuracy in saliva
[0681]
[0682] Table 30 - Accuracy in semen
[0683]
[0684] Table 31 - Accuracy in feces
[0685]
[0686]
[0687] **Feces were suspended in 10 volumes (w:v) of 1X PBS prior to extraction.
[0688] One sample was lost due to clogging.
[0689] Table 32 - Accuracy in urine
[0690]
[0691] Precision - The precision of the intra-laboratory assay was determined using the same set described in the analytical sensitivity (as described above). Each set was tested on multiple days using two instruments with the same reagent batch. The target requirement was ≤30% CV across the quantitative range. Exemplary Hem-B AAV construct shedding assay intra-laboratory precision for each sample type is summarized and presented in Tables 33-38.
[0692] Table 33 – Components of variation in the plasma group
[0693]
[0694] Table 34 - Components of variation in the PBMC* group
[0695]
[0696] *PBMCs were resuspended in cell freezing medium at a concentration of 5E+6 cells / mL.
[0697] Table 35 - Variation components of saliva group
[0698]
[0699] Table 36 - Variation components of semen groups
[0700]
[0701] Table 37 – Components of variation in the feces** group
[0702]
[0703] **Feces were suspended in 10 volumes (w:v) of 1X PBS prior to extraction.
[0704] One sample was lost due to clogging.
[0705] Table 38 – Components of variation in urine group
[0706]
[0707] Individual variability - Individual variability was assessed for each sample type spiked with 1.0E+07 vg / mL of the exemplary Hem-B AAV construct (followed by a 5E+6 cell / mL suspension of PBMCs and a 1:10 (w:v) suspension of feces) using 5 different donors. Three biological replicates of each condition were performed for evaluation. Individual variability was observed to be within the same assay reproducibility / precision range (%CV ≤ 30% and within ±0.5 LOG difference), and the data are presented in Tables 39 and 40. Fig.10 middle.
[0708] Table 39 – Individual variability
[0709]
[0710] *Donors from different sample types are not matched; each sample type has a different donor.
[0711] DNase treatment-MNase is the selected nuclease for DNase treatment. To evaluate the efficiency of nuclease activity, three types of deoxynucleic acid templates were added to saliva, semen, urine and 1X PBS suspended feces: unprotected double-stranded DNA (dsDNA-AAVR), single-stranded DNA (ssDNA-GFP) and encapsulated viral DNA (rAAV-exemplary Hem-B AAV construct). dsDNA-AAVR and ssDNA-GFP were added in parallel with the rAAV exemplary Hem-B AAV construct, and the concentration was 1.0E+07 copies / mL to evaluate the efficiency of nuclease activity. At 37°C, each sample was treated with 4,000 units of MNase, repeated 3 times, continued for 30 minutes, and terminated by adding EDTA. Siemens storage buffer (SSB2) was added in the same manner without MNase treatment to serve as a baseline for recovery calculation. After the MNase reaction was completed, DNA extraction was performed according to methods known in the art.
[0712] Strong endogenous nuclease activity against unprotected deoxynucleic acids (both dsDNA and ssDNA) was observed in PBS suspended fecal samples. Moderate endogenous nuclease activity against ssDNA was also observed in saliva, and to a lesser extent in semen and urine samples. MNase treatment in all sample types depleted unprotected dsDNA and ssDNA templates (reduction>97.5%) without reducing rAAV recovery. Exemplary Hem-B AAV construct MNase treatment results are summarized in Figure 11 and Table 40.
[0713] The effect of MNase treatment on intact viral DNA recovery was further evaluated at concentrations close to the LLoQ in all sample types with a minimum of 12 replicates. For all sample types, no significant differences were observed between MNase-treated or untreated samples, and the results are summarized in Fig.12 and Table 41.
[0714] Table 40 - Summary of percent recovery of rAAV, dsDNA, and ssDNA in the sample types tested with or without MNase treatment
[0715]
[0716] ND = not detected by qPCR.
[0717] Table 41 - Summary of recovery of exemplary HemB AAV constructs in each sample type around LLoQ with or without MNase treatment
[0718]
[0719] Analyte Stability - The stability of exemplary Hem-B AAV constructs was analyzed in untreated whole blood and treated samples - plasma, PBMC, urine, saliva, semen and feces under different conditions.
[0720] Untreated Samples - Room Temperature Stability of Whole Blood - The stability of the exemplary Hem-B AAV constructs in whole blood stored at RT was determined using blood freshly drawn from 3 individual donors and spiked with 1.0E+07 vg / mL of the exemplary Hem-B AAV construct. Plasma was separated after storage of whole blood at room temperature for the indicated times and kept at -80°C until the last time point was collected for plasma shedding assay analysis. Three biological replicates were tested for each condition. Inter-individual variability was observed; one of the donors showed a 0.3-0.7 LOG reduction after 24 h RT incubation. The stability results are summarized in Fig.13 and Table 42.
[0721] Table 42 - Stability of exemplary HemB AAV constructs in whole blood stored at RT
[0722]
[0723] Untreated samples - Room temperature stability of plasma, PBMC, saliva, semen, urine and feces - The stability of the exemplary Hem-B AAV construct viruses in plasma, PBMC, saliva, semen, feces and urine stored at RT was evaluated at various time points. Pooled samples from five donors (later a 5E+6 cells / mL suspension of PBMCs and a 1:10 (w:v) suspension of feces) were spiked with 1.0E+05 vg / mL of the exemplary Hem-B AAV construct and three biological replicates of each condition were tested at the indicated time points. The exemplary Hem-B AAV construct viral genome titers were within ±0.5 LOG of the titer determined at time 0 for up to 48 hours, except for feces, which was stable for up to 24 hours. See Fig.14 And the results are summarized in Table 43.
[0724] Table 43 - Stability samples stored at RT
[0725]
[0726] Freeze / Thaw Stability of Plasma, PBMC, Saliva, Semen, Urine, and Feces - Viral stability of exemplary Hem-B AAV constructs in plasma, PBMC, urine, saliva, semen, and feces was evaluated for up to 4 freeze / thaw cycles. Pooled samples from five donors (later a 5E+6 cell / mL suspension of PBMC and a 1:10 (w:v) suspension of feces) were spiked at 1.0E+05 vg / mL, and three biological replicates of each condition were tested. Exemplary Hem-B AAV construct viral genome titers were within ±0.5 LOG of the starting conditions for up to 4 freeze / thaw cycles. See Fig.15 And the results are summarized in Table 44.
[0727] Table 44 – Summary of sample freeze / thaw stability
[0728]
[0729] Relatively high variability was observed in semen samples using the SASP1.2 kit for extraction and 1 freeze / thaw cycle.
[0730] Long-term -80°C Storage Stability of Plasma, PBMC, Saliva, Semen, Urine, and Feces - The stability of exemplary Hem-B AAV construct viruses in plasma, PBMC, saliva, semen, feces, and urine stored at -80°C was evaluated for up to 6 months. Pooled samples (later a 5E+6 cells / mL suspension of PBMCs and a 1:10 (w:v) suspension of feces) were spiked at 1.0E+05 vg / mL, and three biological replicates of each condition were tested at the indicated time points. Exemplary Hem-B AAV construct viral genome titers were within ±0.5LOG of the titer measured at time 0 for up to 6 months. The long-term -80°C storage stability results are summarized in Fig.16 and Table 45.
[0731] Table 45 - Summary of sample stability during long-term storage at -80°C
[0732]
[0733] * Relatively high variability was observed in semen samples extracted using the SASP1.2 kit at 2 weeks and 6 months.
[0734] References
[0735] All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict, the present application, including any definitions herein, will control.
[0736] Design and Analysis of Shedding Studies for Virus or Bacteria BasedGene Therapy and Oncolytic Products, Guidance for Industry-FDA, 2015.
[0737] Entering the Modern Era of Gene Therapy-Anguela&High, Annu RevMed.2019
[0738] Guidelines on Scientific Requirements for the Environmental RiskAssessment of Gene Therapy Medicinal Products-GTWP.BWP.and SWP.2008
[0739] International Conference Harmonization considerations,GeneralPrinciples to Address Virus and Vector Shedding-ICH,2009
[0740] Malaria parasite evolutionin a test tube-Carlton.Science.2018
[0741] Pharmaceutical Development of AAV-Based Gene Therapy Products for theEve-Rodrigues et al.,Pharm Res.2018
[0742] Recommendationsfor Regulating the Environmental Risk of Shedding forGene Therapy-Bubela et al.Front Med.2019
[0743] Mendell JR,Shilling C,Leslie ND,Flanigan KM,al-Dahhak R,Gastier-Foster J,et al.Evidence-based path to newborn screening for Duchenne musculardystrophy.Ann Neurol.2012;71(3):304-13.doi:10.1002 / ana.23528.
[0744] Moat SJ,Bradley DM,Salmon R,Clarke A,Hartley L.Newbom bloodspotscreening for Duchenne muscular dystrophy:21 years experience in Wales(UK)European joumal of human genetics:EJHG.20l3;21(10):1049-53.doi:10.1038 / ejhg.2012.301.
[0745] Duchenne G-B-A.Paraplegiehypertrophique de I′enfance de causecerebrale1861.
[0746] Birnkrant DJ,Bushby K,Bann CM,Apkon SD,Blackwell A,Brumbaugh D,etal.Diagnosis and management of Duchenne muscular dystrophy,part 1:diagnosis,and neuromuscular,rehabilitation,endocrine,and gastrointestinal andnutritional management.Lancet Neurol,2018;17(3):251-67,doi:10.1016 / S1474-4422(18)30024-3
[0747] Bimkrant DJ,Bushby K,Bann CM,Alman BA,Apkon SD,Blackwell A,etal.Diagnosis and management of Duchenne muscular dystrophy,part 2:respiratory,cardiac,bone health,and orthopaedic management.LancetNeurol.2018;17(4):347-61.doi:10.1016 / S1474-4422(18)30025-5.
[0748] Bimkrant DJ,Bushby K,Bann CM,Apkon SD,Blackwell A,Colvin MK.etal.Diagnosis and management of Duchenne muscular dystrophy,part 3:primarycare.emergency management,psychosocial care,and transitions of care acrossthe lifespan.Lancet Neurol.2018;17(5):445-55.doi:10.1016 / S1474-4422(18)30026-7
[0749] Shieh PB.Emerging Strategies in the Treatment of Duchenne MuscularDystrophy,Neurotherapeutics.2018;15(4):840-848.doi:10.1007 / s13311-018-00687-z
[0750] Guidance for Industry:Design and Analysis of Shedding Studies forVirus or Bacteria-Based Gene Therapy and Oncolytic Products,FDA,August 2015
[0751] Guidance for Industry:Gene Therapy Clinical Trials-Observing Subjectsfor Delayed Adverse Events.FDA,November 2006.
Claims
1. A composition comprising a set of primers, wherein the set of primers comprises: (a) one or more forward primers, comprising a forward primer having a nucleotide sequence according to SEQ ID NO: 1 or an active fragment thereof; and (b) one or more reverse primers, comprising a reverse primer having a nucleotide sequence according to SEQ ID NO: 11 or an active fragment thereof.
2. The composition of claim 1, further comprising: One or more probes comprising a probe having a nucleotide sequence according to SEQ ID NO: 17 or an active fragment thereof.
3. The composition of claim 1 or 2, wherein the one or more forward primers, the one or more reverse primers, the one or more probes, or a combination thereof are DNA.
4. The composition of any one of claims 1-3, wherein the one or more forward primers, the one or more reverse primers, the one or more probes, or a combination thereof, comprise a detectable label.
5. The composition of claim 4, wherein the detectable label does not comprise a nucleotide.
6. The composition of claim 4 or 5, wherein the detectable label is a fluorescent moiety.
7. The composition of any one of claims 1-6, wherein the probe comprises a fluorescent moiety.
8. The composition of claim 7, wherein the probe comprises one or more quenchers.
9. The composition of any one of claims 1 to 8, wherein the active fragment is (a) at least 10 nucleotides in length; (b) at least 15 nucleotides in length; or (c) At least 20 nucleotides in length.
10. The composition of any one of claims 1-9, wherein the composition further comprises a sample obtained from a subject to whom a Duchenne muscular dystrophy (DMD) AAV construct has been administered, wherein the DMD AAV construct comprises one or more regulatory elements and a therapeutic gene of interest, and wherein the sample comprises nucleic acid.
Citation Information
Patent Citations
Alphavirus replicon vector systems
US20060177819A1
Chimeric alphavirus replicon particles
US20090305344A1
Delivery of packaged RNA to mammalian cells
US20150050243A1
Process for preparing polynucleotides
US4458066A
Process for amplifying, detecting, and / or-cloning nucleic acid sequences
US4683195A
Cited By
Sequence composition and kit for detecting tissue distribution and / or expression level of AAV carrier drug
CN121380456A
